EP1358209A2 - Crystallization of igf-1 - Google Patents
Crystallization of igf-1Info
- Publication number
- EP1358209A2 EP1358209A2 EP02724908A EP02724908A EP1358209A2 EP 1358209 A2 EP1358209 A2 EP 1358209A2 EP 02724908 A EP02724908 A EP 02724908A EP 02724908 A EP02724908 A EP 02724908A EP 1358209 A2 EP1358209 A2 EP 1358209A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- igf
- atom
- binding
- igfbp
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002425 crystallisation Methods 0.000 title claims description 39
- 230000008025 crystallization Effects 0.000 title claims description 39
- 101150088952 IGF1 gene Proteins 0.000 title claims description 17
- 238000000034 method Methods 0.000 claims abstract description 135
- 230000027455 binding Effects 0.000 claims abstract description 118
- 239000000556 agonist Substances 0.000 claims abstract description 88
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 80
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 74
- 239000003599 detergent Substances 0.000 claims abstract description 68
- 239000000243 solution Substances 0.000 claims abstract description 56
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 claims abstract description 46
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 claims abstract description 46
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims abstract description 45
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 239000007864 aqueous solution Substances 0.000 claims abstract description 13
- 230000010807 negative regulation of binding Effects 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 449
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 434
- 239000013078 crystal Substances 0.000 claims description 149
- 229910052757 nitrogen Inorganic materials 0.000 claims description 74
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims description 42
- 150000005829 chemical entities Chemical class 0.000 claims description 41
- 102000005962 receptors Human genes 0.000 claims description 40
- 108020003175 receptors Proteins 0.000 claims description 40
- 239000000539 dimer Substances 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 29
- 102000028416 insulin-like growth factor binding Human genes 0.000 claims description 28
- 108091022911 insulin-like growth factor binding Proteins 0.000 claims description 28
- 239000005557 antagonist Substances 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 17
- 125000000539 amino acid group Chemical group 0.000 claims description 17
- 238000009792 diffusion process Methods 0.000 claims description 17
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims description 15
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 claims description 13
- 101100205189 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-5 gene Proteins 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 238000003556 assay Methods 0.000 claims description 11
- 239000001509 sodium citrate Substances 0.000 claims description 11
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 11
- 102000014914 Carrier Proteins Human genes 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 108091008324 binding proteins Proteins 0.000 claims description 8
- SAMYCKUDTNLASP-UHFFFAOYSA-N hexane-2,2-diol Chemical compound CCCCC(C)(O)O SAMYCKUDTNLASP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 239000000816 peptidomimetic Substances 0.000 claims description 7
- 241001515965 unidentified phage Species 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 238000012286 ELISA Assay Methods 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 5
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 238000013500 data storage Methods 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 230000005986 heart dysfunction Effects 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 230000021332 multicellular organism growth Effects 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 208000037824 growth disorder Diseases 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 239000011232 storage material Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 238000009510 drug design Methods 0.000 abstract description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 70
- 108090000623 proteins and genes Proteins 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 43
- 108090000765 processed proteins & peptides Proteins 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 42
- 101100059444 Mus musculus Ccnb1 gene Proteins 0.000 description 39
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 36
- 208000035475 disorder Diseases 0.000 description 35
- 229940125396 insulin Drugs 0.000 description 35
- 108090001061 Insulin Proteins 0.000 description 33
- 102000004877 Insulin Human genes 0.000 description 33
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 30
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 30
- 230000003993 interaction Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 26
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 17
- -1 for example Substances 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 102000044162 human IGF1 Human genes 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000002547 anomalous effect Effects 0.000 description 9
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000001294 propane Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 102000003746 Insulin Receptor Human genes 0.000 description 8
- 108010001127 Insulin Receptor Proteins 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 101150087199 leuA gene Proteins 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 101000701051 Legionella pneumophila Zinc metalloproteinase Proteins 0.000 description 6
- 102000013275 Somatomedins Human genes 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000001508 sulfur Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 4
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 4
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 206010007733 Catabolic state Diseases 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 208000037906 ischaemic injury Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229940126586 small molecule drug Drugs 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 101100228210 Caenorhabditis elegans gly-7 gene Proteins 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 2
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 2
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 2
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 2
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000002367 Retinal Perforations Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000026928 Turner syndrome Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 229940006460 bromide ion Drugs 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- JVAZJLFFSJARQM-RMPHRYRLSA-N (2r,3r,4s,5s,6r)-2-hexoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JVAZJLFFSJARQM-RMPHRYRLSA-N 0.000 description 1
- QFAPUKLCALRPLH-UXXRCYHCSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-nonoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QFAPUKLCALRPLH-UXXRCYHCSA-N 0.000 description 1
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000004834 15N NMR spectroscopy Methods 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
- WGKYSFRFMQHMOF-UHFFFAOYSA-N 3-bromo-5-methylpyridine-2-carbonitrile Chemical compound CC1=CN=C(C#N)C(Br)=C1 WGKYSFRFMQHMOF-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- WKYWHPWEQYJUAT-UHFFFAOYSA-N 7-[3-(aminomethyl)-4-propoxyphenyl]-4-methylquinolin-2-amine Chemical compound CCCOC1=C(C=C(C=C1)C2=CC3=C(C=C2)C(=CC(=N3)N)C)CN WKYWHPWEQYJUAT-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101100126625 Caenorhabditis elegans itr-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 206010053547 Congenital generalised lipodystrophy Diseases 0.000 description 1
- 201000006705 Congenital generalized lipodystrophy Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010755 Conjunctivitis viral Diseases 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 201000005948 Donohue syndrome Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 101800000194 Growth hormone-binding protein Proteins 0.000 description 1
- 102400001066 Growth hormone-binding protein Human genes 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000162682 Heterogen Species 0.000 description 1
- 101000932590 Homo sapiens Cytosolic carboxypeptidase 4 Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000038460 IGF Type 2 Receptor Human genes 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- 101150002416 Igf2 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 208000006302 Laron syndrome Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000035369 Leprechaunism Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001033003 Mus musculus Granzyme F Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- KPNNXHVGOKRBEF-UHFFFAOYSA-N N-hydroxy-7-(2-naphthalenylthio)heptanamide Chemical compound C1=CC=CC2=CC(SCCCCCCC(=O)NO)=CC=C21 KPNNXHVGOKRBEF-UHFFFAOYSA-N 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- JVAZJLFFSJARQM-UHFFFAOYSA-N O-n-hexyl beta-D-glucopyranoside Natural products CCCCCCOC1OC(CO)C(O)C(O)C1O JVAZJLFFSJARQM-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100022239 Peroxiredoxin-6 Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 101710088839 Replication initiation protein Proteins 0.000 description 1
- 206010038886 Retinal oedema Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000036866 Vitreoretinopathy Diseases 0.000 description 1
- 201000011032 Werner Syndrome Diseases 0.000 description 1
- AWSYOWHJNGZJGU-OASARBKBSA-N [(2r,3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COC(=O)CCCCCCC)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 AWSYOWHJNGZJGU-OASARBKBSA-N 0.000 description 1
- JOOSFXXMIOXKAZ-UHFFFAOYSA-H [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O Chemical compound [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O JOOSFXXMIOXKAZ-UHFFFAOYSA-H 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- WOQQAWHSKSSAGF-WXFJLFHKSA-N decyl beta-D-maltopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WOQQAWHSKSSAGF-WXFJLFHKSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 108700001680 des-(1-3)- insulin-like growth factor 1 Proteins 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- HPEGNLMTTNTJSP-LBELIVKGSA-N heptyl 1-thiohexopyranoside Chemical compound CCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HPEGNLMTTNTJSP-LBELIVKGSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002017 high-resolution X-ray diffraction Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000047065 human IGFBP1 Human genes 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 108010026763 insulin-like growth factor binding protein-3 protease Proteins 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940006445 isophane insulin Drugs 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- HWSZZLVAJGOAAY-UHFFFAOYSA-L lead(II) chloride Chemical compound Cl[Pb]Cl HWSZZLVAJGOAAY-UHFFFAOYSA-L 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000022215 lipoatrophic diabetes Diseases 0.000 description 1
- 201000009099 lipoatrophic diabetes mellitus Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000029233 macular holes Diseases 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000000324 molecular mechanic Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 1
- CGVLVOOFCGWBCS-RGDJUOJXSA-N n-octyl β-d-thioglucopyranoside Chemical compound CCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CGVLVOOFCGWBCS-RGDJUOJXSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000000358 protein NMR Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000011195 retinal edema Diseases 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 108010033419 somatotropin-binding protein Proteins 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 230000005469 synchrotron radiation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Definitions
- This invention is directed to a crystalline form of human insulin-like growth factor- 1 (IGF-1) and more particularly to a crystal of human IGF-1, a method of crystallization thereof, and its structure, obtained by x-ray diffraction.
- the invention relates to methods of identifying new IGF-1 agonist molecules based on biophysical and biochemical data suggesting that a single detergent molecule that contacts residues known to be important for IGF-1 binding protein (IGFBP) interactions binds to IGF-1 specifically, and blocks binding of IGFBP-1 and IGFBP-3.
- IGF-1 IGF-1, IGF-2, and IGF variants.
- Human IGF-1 is a serum protein of 70 amino acids and 7649 daltons with a pi of 8.4
- IGFs share a high sequence identity with insulin, being about 49% identical thereto. Unlike insulin, however, which is synthesized as a precursor protein containing a 33-amino-acid segment known as the C-peptide (which is excised to yield a covalently linked dimer of the remaining A and B chains), IGFs are single polypeptides (see Figure 1).
- IGF-1 is a powerful mitogen, regulating diverse cellular functions such as cell cycle progression, apoptosis, and cellular differentiation (LeRoith, Endocrinology, 141: 1287-1288 (2000)).
- IGFs have been implicated in a variety of cellular functions and disease processes, including cell cycle progression, proliferation, differentiation, and insulin-like effects in insulin-resistant diabetes. Thus, IGF has been suggested as a therapeutic tool in a variety of diseases and injuries (for review, see Lowe, Scientific American (March/April 1996), p. 62). Due to this range of activities, IGF-1 has been tested in mammals for such widely disparate uses as wound healing, treatment of kidney disorders, treatment of diabetes, reversal of whole-body catabolic states such as AIDS-related wasting, treatment of heart conditions such as congestive heart failure, and treatment of neurological disorders (Guler et al, Proc. Natl. Acad. Sci.
- the IGF system is also composed of membrane-bound receptors for IGF-1, IGF-2, and insulin.
- the Type 1 IGF receptor (IGF-IR) is closely related to the insulin receptor in structure and shares some of its signaling pathways (Jones and Clemmons, Endocr. Rev., 16: 3-34 (1995)).
- the IGF-2 receptor is a clearance receptor that appears not to transmit an intracellular signal (Jones and Clemmons, supra). Since IGF-1 and IGF-2 bind to IGF-IR with a much higher affinity than to the insulin receptor, it is most likely that most of the effects of IGF-1 and IGF-2 are mediated by IGF-IR (Humbel, Eur. J Biochem.
- IGF-IR is an ⁇ 2 ⁇ 2 heterotetramer of disulfide-linked a and ⁇ subunits. ⁇ ⁇ dimers are themselves disulf ⁇ de linked on the cell surface to form a covalent heterotetramer.
- IGF-1 binds to the IGF-IR with a 1:2 stoichiometry (De Meyts, Diabetologia, 37: S135-S148 (1994)), with a high affinity site (K. about 0.4 oM) and a low affinity site (K. about 6 nM) (Tollefeen and Thompson, J. Biol. Chem., 263: 16267-16273 (1988)).
- the x-ray crystal structure of the first three domains of IGF-IR has been determined (Garrett et al , Nature, 394, 395-399 (1998)). It contains three distinct domains (LI, Cys-rich, L2). Mutations that affect IGF-1 binding map to the concave surface of the receptor.
- IGF-IR is a key factor in normal cell growth and development (Isaksson et al, Endocrine Reviews, 8: 426-438 (1987); Daughaday and Rotwein, Endocrine Rev., 10:68-91 (1989)). Increasing evidence suggests, however, that IGF-IR signaling also plays a critical role in growth of tumor cells, cell transformation, and tumorigenesis (Baserga, Cancer Res., 55:249-252 (1995)).
- the IGFs are potent breast cancer cell mitogens based on the observation that IGF-1 enhanced breast cancer cell proliferation in vitro (Cullen et al, Cancer Res., 50:48-53 (1990)).
- Breast cancers express IGF-2 and IGF-IR, providing all the required effectors for an autocrine-loop-based proliferation paradigm (Quinn g/ fl/., J Biol. Chem., 271:11477-11483 (1996);
- McGen et al, Cancer Res., 56: 1761-1765 (1996) Because breast cancer is a common malignancy affecting approximately one in every eight women and is a leading cause of death from cancer in North American women (LeRoith et al, Aim. Int.
- IGF-1 can suppress apoptosis, and therefore cells lacking IGF-lRs or having compromised IGF-IR signaling pathways may give rise to tumor cells that selectively die via apoptosis (Long et al, Cancer Res., 55:1006-1009 (1995)). Furthermore, it has recently become evident that alterations in IGF signaling in the context of other disease states, such as diabetes, may be responsible for exacerbating the complications of retinopathy (Smith et al, Science, 276:1706-1709 (1997)) and nephropathy (Homey et al, Am. J Physiol. 274: F1045-F1053 (1998)).
- IGF-1 in vivo is mostly found in complex with a family of at least six serum proteins known as IGFBPs (Jones and Clemmons, supra; Bach and Rechler, Diabetes Reviews, 3: 38-61 (1995)), that modulate access of the IGFs to the IGF-IR. They also regulate the concentrations of IGF-1 and IGF-2 in the circulation and at the level of the tissue IGF-IR (Clemmons et al, Anal. NY Acad. Sci. USA, 692:10-21 (1993)).
- the IGFBPs bind IGF-1 and IGF-2 with varying affinities and specificities (Jones and Clemmons, supra; Bach and Rechler, supra).
- IGFBP-3 binds IGF-1 and IGF-2 with a similar affinity
- IGFBP-2 and IGFBP-6 bind IGF-2 with a much higher affinity than they bind IGF-1 (Bach and Rechler, supra; Oh et al, Endocrinology, 132, 1337-1344 (1993)).
- the major carrier protein is IGFBP-3.
- IGF-1 naturally occurs in human body fluids, for example, blood and human cerebral spinal fluid. Although IGF-1 is produced in many tissues, most circulating IGF-1 is believed to be synthesized in the liver.
- the IGFBPs are believed to modulate the biological activity of IGF-1 (Jones and Clemmons, supra), with IGFBP-1 (Lee et al, Proc. Soc. Exp. Biol. & Med., 204: 4-29 (1993)) being implicated as the primary binding protein involved in glucose metabolism (Baxter, "Physiological roles of IGF binding proteins", in: Spencer (Ed.), Modern Concepts of Insulin-like Growth Factors (Elsevier, New York, 1991), pp. 371-380).
- IGFBP-1 production by the liver is regulated by nutritional status, with insulin directly suppressing its production (Suikkari et al, J. Clin. Endocrinol. Metab., 6&. 266-272 (1988)).
- the function of IGFBP-1 in vivo is poorly understood.
- the administration of purified human IGFBP-1 to rats has been shown to cause an acute, but small, increase in blood glucose (Lewitt et al, Endocrinology, 129: 2254-2256 (1991)).
- the regulation of IGFBP-1 is somewhat better understood. It has been proposed (Lewitt and Baxter, Mol.
- IGFBP-1 insulin-binding protein
- IGFBP-1 the growth- stimulating effect of estradiol on the MCF-7 human breast cancer cells is associated with decreased IGFBP- 3 mRNA and protein accumulation, while the anti-estrogen ICI 182780 causes growth inhibition and increased IGFBP-3 mRNA and protein levels (Huynh et al, J Biol. Chem., 271:1016-1021 (1996); Oh et al, Prog. Growth Factor Res., 6:503-512 (1995)).
- IGFBP-3 is a target gene of the tumor suppressor, p53 (Buckbinder et al, Nature, 377:646-649 (1995)). This suggests that the suppressor activity of p53 is, in part, mediated by IGFBP-3 production and the consequential blockade of IGF action (Buckbinder et al, supra). These results indicate that the IGFBPs can block cell proliferation by modulating paracrine/autocrine processes regulated by IGF- l/IGF-2.
- PSA prostate-specific antigen
- IGFBP-3- protease an IGFBP-3- protease, which upon activation, increases the sensitivity of tumor cells to the actions of IGF-1 /IGF-2 due to the proteolytic inactivation of IGFBP-3 (Cohen et al, J. Endocr., 142:407-415 (1994)).
- the IGFBPs complex with IGF- l/IGF-2 and interfere with the access of IGF- l/IGF-2 to IGF-lRs (Clemmons et al ,
- IGFBP-1, -2 and -3 inhibit cell growth following addition to cells in vitro (Lee et al. , J Endocrinol., 152:39 (1997); Feyen et al, J Biol. Chem., 266:19469-19474 (1991)). Further, IGFBP-1 (McGuire et al, J Natl. Cancer Inst, 84:1335-1341(1992); Figueroa et al, J Cell Physiol., 157:229-236 (1993)), IGFBP-3 (Oh et al. (1995), supra; Pratt and Pollak, Biophys. Res.
- IGFBP-2 have all been shown to inhibit IGF-1 or estrogen-induced breast cancer cell proliferation at nanomolar concentrations in vitro.
- IGFs have mitogenic and anti-apoptotic influences on normal and transformed prostate epithelial cells (Hsing et al, Cancer Research, 56: 5146 (1996); Culig et al, Cancer Research, 54: 5474 (1994); Cohen et al., Hormone and Metabolic Research, 26: 81 (1994); Iwamura et al, Prostate, 22: 243 (1993); Cohen et al, J. Clin. Endocrin. & Metabol., 73: 401 (1991); Rajah et al, J. Biol. Chem., 272: 12181 (1997)).
- IGF-1 Most circulating IGF-1 originates in the liver, but IGF bioactivity in tissues is related not only to levels of circulating IGFs and IGFBPs, but also to local production of IGFs, IGFBPs, and IGFBP proteases (Jones and Clemmons, Endocrine Reviews, 16: 3 (1995)). Person-to-person variability in levels of circulating IGF-1 and IGFBP-3 (the major circulating IGFBP (Jones and Clemmons, supra)) is considerable (Juul et al, J. Clin. Endocrinol. & Metabol, 78: 744 (1994); Juul et al, J. Clin. Endocrinol.
- the IGFs are present in high concentrations in the circulation, but only a small fraction of the IGFs is not protein bound. For example, it is generally known that in humans or rodents, less than 1% of the IGFs in blood is in a "free" or unbound form (Juul et al, Clin. Endocrinol., 44: 515-523 (1996); Hizuka et al, Growth Regulation, 1: 51-55 (1991); Hasegawa et al, J. Clin. Endocrinol. Metab., 80: 3284-3286 (1995)).
- the ternary complex of an IGF, IGFBP-3, and ALS has a molecular weight of approximately 150,000 daltons, and it has been suggested that the function of this complex in the circulation may be to serve as a reservoir and buffer for IGF-1 and IGF-2, preventing rapid changes in free IGF-1 or IGF-2.
- IGF-1 and IGF- 2 are used to bind to the IGFBPs from those used to bind to IGF-IR. It is therefore possible to produce IGF variants that show reduced binding to the IGFBPs, but, because they bind well to IGF-IR, show maintained activity in in vitro activity assays.
- IGF variant that binds to IGFBPs but not to IGF receptors and therefore shows reduced activity in in vitro activity assays (Bar et al, Endocrinology, 127: 3243-3245 (1990)).
- this variant designated (1-27-gly 4 , 38-70)-hIGF-l, residues 28-37 of the C-region of human IGF-1 are replaced by a' four-residue glycine bridge.
- IGF-1 variants are disclosed.
- EP 742,228 discloses two-chain IGF- 1 superagonists, which are derivatives of the naturally occurring, single-chain IGF-1 having an abbreviated C-region.
- the IGF-1 analogs are of the formula: BC n ,A wherein B is the B-region of IGF-1 or a functional analog thereof, C is the C-region of IGF-1 or a functional analog thereof, n is the number of amino acids in the C-region and is from about 6 to about 12, and A is the A-region of IGF-1 or a functional analog thereof.
- Cascieri et al, Biochemistry, 27: 3229-3233 (1988) discloses four mutants of IGF-1, three of which have reduced affinity to IGF-IR. These mutants are: (Phe 23 ,Phe 24 ,Tyr 25 )IGF-l (which is equipotent to human IGF-1 in its affinity to the Types 1 and 2 IGF and insulin receptors), (Leu 24 )IGF-l and (Ser 24 )IGF-l (which have a lower affinity than IGF-1 to the human placental IGF-IR, the placental insulin receptor, and the IGF-IR of rat and mouse cells), and desoctapeptide (Leu 24 )IGF-l (in which the loss of aromaticity at position 24 is combined with the deletion of the carboxyl-terminal D-region of hIGF-1, which has lower affinity than (Leu 24 )IGF-l for the IGF-IR and higher affinity for the insulin receptor). These four mutants have normal affinities for human serum
- WO 94/04569 discloses a specific binding molecule, other than a natural IGFBP, that is capable of binding to IGF-1 and can enhance the biological activity of IGF-1.
- WO 00/23469 discloses the portions of IGFBP and IGF peptides that account for IGF-IGFBP binding, i.e., an isolated IGF binding domain of an IGFBP or modification thereof that binds IGF with at least about the same binding affinity as the full-length IGFBP.
- EP 639981 discloses pharmaceutical compositions comprising short peptides that function as IGF-1 receptor antagonists.
- the peptides used in the pharmaceutical compositions consist of less than 25 amino acids, comprise at least a portion of the C- or D-region from IGF-1, and inhibit IGF-1- induced autophosphorylation of IGF-1 receptors.
- Polypeptides including the IGF molecules, have a three-dimensional structure determined by the primary amino acid sequence and the environment surrounding the polypeptide. This three-dimensional structure establishes the activity, stability, binding affinity, binding specificity, and other biochemical attributes of the polypeptide. Thus, knowledge of the three-dimensional structure of a protein can provide much guidance in designing agents that mimic, inhibit, or improve its biological activity in soluble or membrane-bound forms.
- the three-dimensional structure of a polypeptide may be determined in a number of ways. Many of the most precise methods employ x-ray crystallography (Van Holde, Physical Biochemistry (Prentice
- insulin crystal suspensions that are used therapeutically include suspensions of rhombohedral zinc-insulin crystals that are stable in the presence of 0.8 to 2.5% of zinc (based on the weight of insulin) at a neutral pH value and exhibit a delayed action, and isophane insulin protamine crystals, which are used in delayed action products in the form of small rods.
- a few other crystal modifications of insulin are furthermore known, but these have hitherto been of interest only for X-ray structure analysis. Thus, zinc-free orthorhombic and monoclinic crystals have been obtained under acid pH conditions (Einstein and Low, Acta Crystallogr., L5: 32-34 (1962)).
- a protein of sufficient purity it must be crystallized to a size and clarity that is useful for x-ray diffraction and subsequent structure resolution.
- this sequence information does not allow an accurate prediction of the crystal structure of the protein.
- sequence information afford an understanding of the structural, conformational, and chemical interactions between a ligand such as an IGFBP and its protein target.
- crystal structures can provide a wealth of valuable information in the field of drug design and discovery, crystals of certain biologically relevant compounds such as IGF-1 are not readily available to those skilled in the art. High-quality, diffracting crystals of IGF-1 would assist the determination of its three-dimensional structure.
- IGF- 1 antagonists have been restricted, at least in part, because of difficulties in studying the structure of IGF and IGFBPs. Due to the inability to obtain crystals of IGF-1 suitable for diffraction studies, for example, an extrapolation of IGF-1 structure based on the crystal structure of porcine insulin was the most important structural road map for IGF-1 available (Blundell et al. , Proc. Natl Acad. Sci. USA , 75:180- 184 (1978)). See also Blundell et al, Fed. Proc, 42: 2592-2597 (1983), which discloses tertiary structures, receptor binding, and antigenicity of IGFs. Based on studies of chemically modified and mutated IGF-1, a number of common residues between IGF- 1 and insulin have been identified as being part of the IGF-lR-insulin receptor contact site, in particular, the aromatic residues at positions 23-25.
- Biol Chem., 275: 10009-10015 (2000) discloses the solution structure and backbone dynamics of long-[Arg(3)]IGF-l . See also Laajoki et al, FEBS Lett., 420: 97-102 (1997)).
- the small number of NMR models available for IGF-1 are not very well defined, as there are large RMSDs between the backbone atoms of the helical segments.
- the best NMR model is of IGF-2 in which three alpha-helices are shown. See Torres et al, J. Mol Biol, 248: 385-401 (1995), which discloses the solution structure of human IGF-2 and its relationship to receptor and binding protein interactions. In all structures, the C- and D-regions are very poorly defined.
- crystalline polypeptides provide other advantages. For example, the crystallization process itself further purifies the polypeptide and satisfies one of the classical criteria for homogeneity. In fact, crystallization frequently provides unparalleled purification quality, removing impurities that are not removed by other purification methods such as HPLC, dialysis, conventional column chromatography, etc. Moreover, crystalline polypeptides are often stable at ambient temperatures and free of protease contamination and other degradation associated with solution storage. Crystalline polypeptides may also be useful as pharmaceutical preparations. Finally, crystallization techniques in general are largely free of problems such as denaturation associated with other stabilization methods (e.g. lyophilization).
- crystallographic data provides useful structural information that may assist the design of peptides that may serve as agonists or antagonists.
- the crystal structure provides information useful to map the receptor-binding domain, which could then be mimicked by a small non-peptide molecule that may serve as an antagonist or agonist.
- findings regarding the detergent's inhibition of the binding of IGFBP to IGF-1 can be used to identify new IGF-1 agonists.
- IGF-1 has been crystallized and its structure determined using multiwavelength anomalous diffraction (MAD) at 1.8 angstroms resolution by exploiting the anomalous scattering of a single bromide ion and six of the seven sulfur atoms of IGF-1.
- the C-region of IGF-1 which is ordered in the crystal structure, forms a type II beta-turn and mediates a crystal packing interaction across a crystallographic dyad.
- the solution state of IGF-1 was characterized by analytical ultracentrifugation, and the results indicate that IGF-1 exists primarily as a monomer at neutral pH, with only a slight tendency to dimerize at millimolar concentrations.
- a molecule of detergent N, N-bis(3-D- gluconamidopropyl)-deoxycholamine (deoxy big CHAPS), mediates a crystal packing contact between symmetry-related molecules.
- Solution experiments confirm that the IGF-1 :N, N-bis(3-D- gluconamidopropyl)-deoxycholamine complex does form in solution, and that detergent binding measurably blocks IGFBP binding.
- the invention provides a crystal formed by IGF-1 that diffracts x-ray radiation to produce a diffraction pattern representing the three-dimensional structure of the IGF-1.
- the IGF-1 contains an A-, B-, C-, and D-region and forms a dimer in the crystal, and further preferred is the crystal comprising a receptor binding site at the dimer interface.
- the invention also provides a composition comprising the above crystal.
- the IGF-1 is biologically active when resolubilized.
- the invention further provides a method of treating a mammal suffering from an agonist disorder, preferably a human patient, said method comprising administering to said mammal an effective amount of the above resolubilized composition.
- the invention also provides a method of crystallizing IGF-1 comprising the steps of:
- the invention also provides crystalline IGF-1 produced by the above method. Additionally, the invention provides a method for determining a three-dimensional structure of IGF-1 comprising: (a) crystallizing the IGF- 1 ;
- the invention provides a machine-readable data storage medium comprising a data storage material encoded with machine-readable data that, when read by an appropriate machine, displays a three- dimensional representation of a crystal of a molecule comprising IGF-1.
- the invention provides an IGF-1 crystal with the structural coordinates shown in Appendix 1.
- the invention provides a method of using a three-dimensional structure of IGF-1 derived from an IGF-1 crystal wherein the three-dimensional structure of IGF-1 includes an IGF-1 receptor- binding region, the method comprising identifying compounds having structures that interact with the receptor-binding region of the three-dimensional structure of IGF-1 and function as an IGF-1 agonist or antagonist.
- the three-dimensional structure of IGF-1 includes alpha-carbon coordinates substantially the same as those of the structural information presented in Appendix 1.
- the invention provides a method of identifying IGF-1 agonists or antagonists comprising the steps of:
- step (b) irradiating the IGF-1 crystals from step (a) to obtain a diffraction pattern -of the IGF-1 crystals; (c) determining a three-dimensional structure of IGF-1 from the diffraction pattern, the structure including an IGF-1 receptor-binding region; and
- IGF-1 agonist or antagonist having a three-dimensional structure that functionally duplicates essential IGF receptor-binding, solvent-accessible residues presenting the three- dimensional structure of the IGF-1 receptor-binding region, said IGF-1 agonist or antagonist having altered signal transduction capacity to IGF-1 -responsive cells, as compared to IGF-1.
- the solvent-accessible residues do not participate in formation of the IGF-1 interface.
- the invention includes a method of designing a compound, such as a peptidomimetic, that mimics the 3-dimensional surface structure of IGF-1 comprising the steps of: (a) dete ⁇ nining the 3-dimensional structure of the IGF-1; and (b) designing a compound that mimics the 3-dimensional surface structure of the IGF-1.
- the invention provides a method for identifying a peptidomimetic that binds IGF-1 and blocks binding of an IGFBP or a receptor that binds to IGF-1 comprising the steps of: (a) searching a molecular structure database with the structural parameters or structural coordinates provided in Appendix 1; and
- the invention also provides a method for determining at least a portion of a three-dimensional structure of a molecular complex, said complex comprising IGF-1 and said method comprising the steps of:
- step (c) calculating an electron density map from the phases obtained in step (b);
- the structural coordinates used in step (a) are substantially the same as those described in Appendix 1 or describe substantially the same crystal as the coordinates in Appendix 1.
- the invention also provides a method for evaluating the ability of a chemical entity to associate with IGF-1 or a complex thereof, the method comprising the steps of: (a) employing computational or experimental means to perform a fitting operation between the chemical entity and the IGF-1 or complex thereof, thereby obtaining data related to the association; and (b) analyzing the data obtained in step (a) to determine the characteristics of the association between the chemical entity and the IGF-1 or complex thereof.
- the invention also provides a chemical entity identified by the above method that interferes with the in vivo or in vitro association between IGF-1 and its receptor or between IGF-1 and at least one of its binding proteins, or associates with a binding site on IGF-1.
- the invention also comprises a method of computationally or experimentally evaluating a chemical entity to obtain information about its association with one or more binding sites of IGF-1 using a crystal of IGF-1 having the structural coordinates described in Appendix 1.
- the invention also provides a method of identifying indirect agonists of IGF-1 comprising the steps of:
- the comparison is accomplished by competition assay between N, N- bis(3-D-gluconamidopropyl)-deoxycholamine and the candidate agonist.
- inhibition of binding is measured by pre-incubating N, N-bis(3-D-gluconamidopropyl)-deoxycholamine or the candidate agonist with IGF-1 expressed on bacteriophage particles and measuring residual binding of IGF-1 to IGFBP-1 or IGFBP-3 in a plate-based ELISA assay.
- the invention further provides a method of identifying indirect agonists of IGF-1 comprising co- crystallizing a candidate indirect agonist of IGF-1 with IGF-1 to form a co-crystalline structure and determining if the candidate agonist binds to one or both of two patches on IGF-1, wherein one patch has the amino acid residues Glu 3, Thr 4, Leu 5, Asp 12, Ala 13, Phe 16, Val 17, Cys 47, Ser 51, Cys 52, Asp 53, Leu 54, and Leu 57, and the second patch has the amino acid residues Val 11, Gin 15, Phe 23, Phe 25,
- the candidate agonist inhibits binding of IGFBP- 1 or -3 to IGF-1 at least as well as N, N-bis(3-D-gluconamido ⁇ ropyl)-deoxycholamine. More preferred is the method wherein inhibition of binding is measured using a competition assay between N, N-bis(3-D- gluconamidopropyl)-deoxycholamine and the candidate agonist.
- the method wherein inhibition of binding is measured by pre-incubating N, N-bis(3-D-gluconamidopropyl)-deoxycholamine or the candidate agonist with IGF-1 expressed on bacteriophage particles and measuring residual binding of IGF-1 to IGFBP-1 or IGFBP-3 in a plate-based ELISA assay.
- a method for treating an IGF-1 agonist disorder in a mammal comprising administering to the mammal an effective amount of N, N-bis(3-D-gluconamido ⁇ ro ⁇ yl)-deoxycholamine.
- Figure 1 aligns the sequences of IGF-1 (SEQ ID NO:l), IGF-2 (SEQ ID NO:2), and insulin (SEQ ID NO:3).
- the A-, B-, and C-chains of insulin (and the sequences of IGF-1 and IGF-2 corresponding thereto) are shown respectively in bold, underlined, and italicized text.
- the three aromatic residues are shown by outlining the text.
- the residues marked with a (!) have been demonstrated to be important for binding to the IGF-1 receptor.
- the residues marked with a "*" have been shown to be important for binding to IGFBP-1 and IGFBP-3.
- the carboxyl-terminal residues comprising the D-region of IGF-1 and IGF-2 are depicted in regular type.
- Figure 2 is a ribbon diagram of IGF-1 showing the backbone fold. In the Ramachandran plot, 91.1% is most favored and 2.3% is allowed.
- Figure 3 is a ribbon diagram of both IGF-1 (left structure) and insulin (right structure).
- Figure 4 is a ribbon diagram of IGF-1 showing that the detergent used in the reservoir solution, (N, N-bis(3-D-gluconamidopro ⁇ yl)-deoxycholamine), binds into a small hydrophilic cleft at the base of the B- helix.
- the detergent is represented by lighter gray structures than the IGF-1 structures.
- Figure 5 is a ribbon diagram of IGF-1 as a dimer, with the detergent shown in lighter gray.
- Figure 6 is a ribbon diagram of IGF-1 as a dimer, showing that the residues important for receptor binding (indicated by ring structures in the center portion of the figure) cluster at the dimer interface. The detergent is shown in lighter gray at the outer portions of the figure.
- Figures 7 A and 7B are ribbon diagrams of IGF-1 demonstrating, as does Fig. 4, that the detergent used in the reservoir solution (N, N-bis(3-D-gluconamidopropyl)-deoxycholamine), shown in stick form, binds into a small hydrophilic cleft at the base of the B-helix.
- the detergent head group is inserted into the cleft lined by residues Leu 5, Phe 16, Val 17, Leu 54, and Leu 57.
- the various shades of gray are according to the alanine-scanning mutagenesis results of Dubaquie and Lowman, supra, with the Phe 16, Val 17, and Leu 5 regions indicating a 5-10 fold reduction, the Glu 3 region a 10-100 fold reduction, and the Pro 63 and Pro 63' regions a >100 fold reduction in affinity for IGFBP-1.
- the black part at the far right corresponds to the symmetry-related IGF-1 molecule that forms the crystallographic dimer.
- the circle near Leu 54 indicates the CIO atom of the detergent, which differs from another detergent (3-((3- cholamidopropyl) dimethylammonio)-l-propane sulphonate; or CHAPS) by having a hydroxyl group at this position.
- Fig. 7B shows the view from the opposite surface of the detergent and depicts the interactions of the detergent molecule with a symmetry-related IGF-1 molecule.
- the various shades of gray are according to the alanine-scanning mutagenesis results of Dubaquie and Lowman, supra, with the group near Gin 15 indicating a 5-10 fold reduction, the far left medium gray molecules, the Leu 10 region molecules, and the far right medium gray region indicating a 10-100 fold reduction, and the black regions at Phe 49 and Gly 7 indicating a >100 fold reduction in affinity for IGFBP-1.
- the black regions to the right of the detergent molecule correspond to the symmetry-related IGF-1 molecule that forms the crystallographic dimer.
- the circle near Gin 15 indicates the CIO atom of the detergent, as noted above for Fig. 7A. This figure was prepared using INSIGHT (MSI, San Diego, CA).
- Figure 8 shows a graph resulting from a detergent IGFBP competition binding study.
- N N-bis(3-D-gluconamidopropyl)-deoxycholamine was used as a competitive inhibitor of IGF- 1 binding to immobilized IGFBP-1 (closed squares) or IGFBP-3 (open circles).
- soluble IGFBP-1 was used as a competitive inhibitor of IGF-1 binding to immobilized IGFBP-1 (closed triangles).
- Each data point represents the average of two independent experiments.
- Figure 9 A shows a non-linear least-squares analysis of sedimentation equilibrium data for IGF-1 in solution. Data collected at rotor speeds of 30,000 rpm (open triangles) and 35,000 rpm (open squares) were fit as an ideal monomer-dimer self-association model. The solid lines are the fits of the data.
- Figure 9B shows the residuals plotted for both rotor speeds after accounting for the data by the fitting procedure. They are randomly distributed around zero, indicating that the monomer-dimer model is correct for this interaction.
- Figure 10A shows a ribbon diagram determined by NMR of a complex of IGF- 1 and N, N-bis(3 -D- gluconamidopropyl)-deoxycholamine), and Figure 10B shows a ribbon diagram determined by NMR of a complex of IGF-1 bound to a phage-derived IGF-1 antagonist peptide designated IGF-F1-1.
- Figure 10B shows a ribbon diagram determined by NMR of a complex of IGF-1 bound to a phage-derived IGF-1 antagonist peptide designated IGF-F1-1.
- IGF-1 refers to human insulin-like growth factor- 1 unless otherwise noted, and has the human native mature IGF-1 sequence without a N-terminal methionine, as described, for example, by EP 230,869 published August 5, 1987; EP 128,733 published December 19, 1984; or EP 288,451 published October 26, 1988.
- IGFBP insulin growth factor
- IGFBP-7 prostacyclin-stimulating factor
- ESM-1 endothelial cell-specific molecule
- IGFBP-1 and IGFBP-3 bind to different residues of IGF-1.
- human IGF-1 receptor or just “IGF-1 receptor” refers to any receptor for IGF-1 found in humans and includes the Type 1 and Type 2 IGF receptors in humans to which human IGF-1 binds, such as the placental IGF-IR, etc.
- IGF-1 an "indirect agonist of IGF-1" is a molecule that releases IGF-1 in situ from IGFBP-3 or IGFBP-1 so that the IGF-1 released is active and interacts with its receptor.
- Proteins are molecules having at least two amino acids and include polypeptides having at least about 60 amino acids. Preferably, the peptides have about 10 to about 60 amino acids, more preferably about 10-25, and most preferably about 12-25 amino acids.
- the definition includes linear and cyclic peptides, peptide derivatives, their salts, or optical isomers.
- mammal for purposes of treatment refers to any animal classified as a mammal, including humans, domestic, and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, sheep, pigs, cows, etc.
- the preferred mammal herein is a human.
- non-adult refers to mammals that are from perinatal age (such as low-birth-weight infants) up to the age of puberty, the latter being those that have not yet reached full growth potential.
- treating refers to both therapeutic treatment and prophylactic or preventative measures.
- Those in need of treatment include those already with the disorder as well as those prone to having the disorder or diagnosed with the disorder or those in which the disorder is to be prevented.
- a “disorder” is any condition that would benefit from treatment with an IGF-1 agonist ("agonist disorder”) or antagonist (“antagonist disorder”). This includes chronic and acute disorders or diseases including those pathological conditions that predispose the mammal to the disorder in question.
- the disorder being treated may be a combination of two or more of the agonist or antagonist disorders listed below.
- Non-limiting examples of antagonist disorders include benign and malignant tumors, leukemias and lymphoid malignancies, neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders, and inflammatory, angiogenic and immunologic disorders, diabetic complications such as diabetic retinopathies or neuropathies, age-related macular degeneration, ophthalmic surgery such as cataract extraction, a corneal transplant, glaucoma filtration surgery and keratoplasty, surgery to correct refraction, i.e., a radial keratotomy, also in sclera macular holes and degeneration, retinal tears, vitreoretinopathy, miscellaneous disorders, cataract disorders of the cornea such as the sequelae of radial keratotomy, dry eye, viral conjunctivitis, ulcerative conjunctivitis, wounds such as corneal epithelial wounds, Sjogren'
- such antagonist disorders include diabetic complications exacerbated by IGF-1, ischemic injury, and diseases associated with undesirable cell proliferation such as cancer, restenosis, and asthma.
- the disorder is a diabetic complication exacerbated by IGF-1, such complication can include diabetic retinopathy or diabetic nephropathy.
- the efficacy of the treatment can be evidenced by a reduction in clinical manifestations or symptoms, including, for example, improved renal clearance, improved vision, or a reduction in the amount of IGF-1 available for binding to an IGF-1 receptor.
- the disorder is an ischemic injury, it can include strokes, myocardial ischemia, and ischemic injury to the kidneys.
- agonist disorders for purposes herein include any condition that would benefit from treatment with an IGF-1, including but not limited to, for example, lung diseases, hyperglycemic disorders as set forth below, renal disorders, such as acute and chronic renal insufficiency, end-stage chronic renal failure, glomerulonephritis, interstitial nephritis, pyelonephritis, glomerulosclerosis, e.g., Kimmelstiel- Wilson in diabetic patients and kidney failure after kidney transplantation, obesity, GH-insufficiency, Turner's syndrome, Laron's syndrome, short stature, undesirable symptoms associated with aging such as obesity and increased fat mass-to-lean ratios, immunological disorders such as immunodeficiencies including decreased CD4 counts and decreased immune tolerance or chemotherapy-induced tissue damage, bone marrow transplantation, diseases or insufficiencies of cardiac structure or function such as heart dysfunctions and congestive heart failure, neuronal, neurological, or neuromuscular disorders, e.g., peripheral
- hyperglycemic disorders refers to all forms of diabetes and disorders resulting from insulin resistance, such as Type I and Type II diabetes, as well as severe insulin resistance, hyperinsulinemia, and hyperlipidemia, e.g., obese subjects, and insulin-resistant diabetes, such as Mendenhal-'s Syndrome, Werner Syndrome, leprechaunism, lipoatrophic diabetes, and other lipoatrophies.
- the preferred hyperglycemic disorder is diabetes, especially Type 1 and Type II diabetes.
- Diabetes itself refers to a progressive disease of carbohydrate metabolism involving inadequate production or utilization of insulin and is characterized by hyperglycemia and glycosuria.
- Biologically active IGF-1 refers to IGF-1 that exhibits a biological property conventionally associated with an IGF-1 agonist or antagonist, such as a property that would allow treatment of one or more of the disorders listed above.
- the term "effective amount” refers to an amount of IGF-1 or a peptidomimetic or other compound, including chemical entities, effective to treat a disease or disorder in a mammal.
- the effective amount of the peptide may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow at least to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; promote apoptosis; and/or relieve to some extent one or more of the symptoms associated with the disorder.
- a “precipitant” is an agent in a reservoir solution that precipitates IGF-1 when mixed with an aqueous solution of IGF-1 and allowed to equilibrate so as to form IGF-1 crystals.
- examples include chaotropic agents such as ammonium sulfate, polyethylene glycols (of a wide variety of molecular weights ranging, for example, from about 2000 to 20,000), sodium citrate, sodium cacodylate, or a mixture thereof.
- a “reservoir solution” is a solution of a precipitant and any other ingredient needed to provide
- IGF-1 crystals for example, a detergent such as C E Albany (nonaethylene glycol monododecyl ether, nonaethylene glycol monolauryl ether, polyoxyethylene (9) ether), C. 2 E g (octaethylene glycol monododecyl ether, octaethylene glycol monolauryl ether, polyoxyethylene (8) lauryl ether), dodecyl-beta-D- maltopyranoside, lauric acid sucrose ester, cyclohexyl-pentyl-beta-D-maltoside, nonaethylene glycol octylphenol ether, cetyltrimethylammonium bromide, decyl-beta-D-maltopyranoside, lauryldimethylamine oxide, cyclohexyl-pentyl-beta-D-maltoside, n-dodecylsulfobetaine, 3-(dodecy
- the detergent is N, N-bis(3-D- gluconamidopropyl)-deoxycholamine.
- Recrystallization refers to the procedure, after the initial crystals are grown and determined not to be very large or useful, of adding a substance to the crystals, such as methyl pentanediol, which has the effect of dissolving the crystals, but not diluting anything else much in the crystallization mixture. Then over the course of several days, as the crystallization droplet re-equilibrates with its reservoir solution, the crystals regrow, but this time much larger and more well ordered.
- association refers to a condition of proximity between IGF-1 and a chemical entity, or portions thereof.
- the association may be non-covalent, wherein the juxtaposition is energetically favored by hydrogen bonding, van der Waals interaction, or electrostatic interaction, or it may be a covalent association.
- binding site refers to any or all of the sites where a chemical entity binds or associates with IGF-1.
- structural coordinates refers to the coordinates derived from mathematical equations related to the patterns obtained on diffraction of a monochromatic beam of x-rays by the atoms (scattering centers) of a molecule in crystal form. The diffraction data can be used to calculate an electron density map of the repeating units of the crystal Those skilled in the art will understand that the data obtained are dependent upon the particular system used, and hence, different coordinates may in fact describe the same crystal if such coordinates define substantially the same relationship as those described herein. An electron density map may be used to establish the positions of the individual atoms within the unit cell of the crystal.
- Appendix 1 shows the atomic coordinates of IGF-1.
- any set of structural coordinates of IGF-1 that have a root mean square deviation of equivalent protein backbone atoms of less than about 2 A when superimposed—using backbone atoms— on the structural coordinates in Appendix 1 shall be considered identical
- the deviation is less than about 1 A and more preferably less than about 0.5 A.
- the term "heavy-atom derivatization” refers to a method of producing a chemically modified form of a crystallized IGF-1.
- a crystal is soaked in a solution containing heavy metal atom salts, or organometallic compounds, e.g., lead chloride, gold thiomalate, thimerosal, or uranyl acetate, which can diffuse through the crystal and bind to the surface of the protein.
- the location of the bound heavy metal atom(s) can be determined by x-ray diffraction analysis of the soaked crystal. This information can be used to generate the phase information used to construct the three-dimensional structure of the molecule.
- unit cell refers to a basic shaped block The entire volume of a crystal may be constructed by regular assembly of such blocks. Each unit cell comprises a complete representation of the unit of pattern, the repetition of which builds up the crystal.
- space group refers to the arrangement of symmetry elements of a crystal
- molecular replacement refers to a method that involves generating a preliminary structural model of a crystal whose structural coordinates are unknown, by orienting and positioning a molecule whose structural coordinates are known, e.g., the IGF-1 coordinates in Appendix 1, within the unit cell of the unknown crystal, so as to best account for the observed diffraction pattern of the unknown crystal Phases can then be calculated from this model, and combined with the observed amplitudes to give an approximated Fourier synthesis of the structure whose coordinates are unknown. This in turn can be subject to any of the several forms of refinement to provide a final accurate structure of the unknown crystal.
- molecular replacement may be used to determine the structural coordinates of a crystalline co- complex, unknown ligand, mutant, or homolog, or of a different crystalline form of IGF-1. Additionally, the claimed crystal and its coordinates maybe used to determine the structural coordinates of a chemical entity that associates with IGF-1.
- chemical entity or "compound” as used herein means any molecule, molecular complex, compound, peptidomimetic, or fragment thereof that is not IGF-1. Preferably it is a molecule with high oral bioavailability, such as an organic chemical molecule, or a peptide.
- the following detailed description of the invention encompasses the crystal structure of IGF-1, methods of making an IGF-1 crystal, and methods of using an IGF-1 crystal and its structural coordinates.
- the ribbon structure thereof is shown in Figure 2 having three helices, with the N-terminal B-region corresponding to residues 3-28, the C-region from residues 29-34, a stretch of poorly ordered residues from residues 35-40, and the A-region from residues 42-62.
- the D-region (residues 63-70) is essentially disordered.
- Figures 4 and 7 show that the detergent used in the crystallization binds into a small hydrophobic cleft at the base of the B-helix of the structure.
- the IGF-1 can form a dimer in the crystal, as shown in Fig. 5, wherein the two tails are positioned at the dimer interface.
- the buried surface area is 689 A 2 /monomer, which is 1378 A 2 total
- the residues important for IGF-IR binding cluster at the dimer interface as shown in Figure 6.
- the claimed invention relates to methods of preparing crystalline forms of IGF-1 by first providing an aqueous solution comprising IGF- 1.
- a reservoir solution comprising a precipitant is then mixed with a volume of the IGF-1 solution and the resultant mixed volume is then crystallized.
- the crystals are again dissolved and recrystallized.
- An example of a reagent that can be used for recrystallization is methyl pentanediol, which is preferred.
- the crystals are typically dissolved with this reagent in a small amount to minimize dilution effects of the other reagents and left to regrow for a period of time.
- the crystalline IGF-1 is isolated from the mixed volume.
- the IGF-1 is obtained from a prokaryotic cell, more preferably a bacterial cell, most preferably E. coli. Preferably it is secreted into the periplasm and prepared as described in U.S. Pat. No. 5,723,310.
- the concentration of IGF-1 in the aqueous solution may vary, but is preferably about 1 to 50 mg/ml, more preferably about 5 to 15 mg/ml.
- precipitants used in the invention may vary, and may be selected from any precipitant known in the art.
- the precipitant is selected from the group consisting of sodium citrate, ammonium sulfate, polyethylene glycol, sodium cacodylate, or a mixture thereof. More preferably the precipitant is polyethylene glycol buffered with sodium citrate or sodium cacodylate.
- the reservoir solution further comprises a detergent.
- the detergent is present in an amount of about 10 to 50 mM.
- the detergent is N, N-bis(3-D-gluconamidopropyl)-deoxycholamine.
- the pH of the reservoir solution may also be varied, preferably between about 4 to 10, most preferably about 6.5.
- Various methods of crystallization can be used in the claimed invention, including vapor diffusion, batch, liquid-bridge, or dialysis crystallization. Vapor diffusion crystallization is preferred. See, e.g.
- a small volume i.e., a few milliliters
- a solution containing a precipitant i.e., a small amount, i.e. about 1 ml, of precipitant. Vapor diffusion from the drop to the well will result in crystal formation in the drop.
- the dialysis method of crystallization utilizes a semipermeable size-exclusion membrane that retains the protein but allows small molecules (i.e. buffers and precipitants) to diffuse in and out.
- small molecules i.e. buffers and precipitants
- the precipitant is allowed to slowly diffuse through the membrane and reduce the solubility of the protein while keeping the protein concentration fixed.
- the batch methods generally involve the slow addition of a precipitant to an aqueous solution of protein until the solution just becomes turbid; at this point the container can be sealed and left undisturbed for a period of time until crystallization occurs.
- a precipitant to an aqueous solution of protein until the solution just becomes turbid; at this point the container can be sealed and left undisturbed for a period of time until crystallization occurs.
- the claimed invention encompass any and all methods of crystallization.
- One skilled in the art can choose any of such methods and vary the parameters such that the chosen method results in the desired crystals.
- the most preferred method of crystallization involves the method wherein the IGF-1, after isolation from the cell and formulation in, for example, an acetate, citrate, or succinate buffer, as described, for example, in U.S. Pat. No. 5,681,814 and WO 99/51272, is optionally desalted if necessary to apH of about 4-5, preferably about 4.5, to fo ⁇ n an aqueous solution.
- a droplet of the aqueous solution is mixed with about 24% polyethylene glycol buffered to about pH 6.5 with either about 0.1M sodium citrate or about 0.1M sodium cacodylate and with about 1 ⁇ l of about 1.4 mM N, N-bis(3-D-gluconamidopropyl)- deoxycholamine as detergent.
- This solution is then equilibrated by vapor diffusion crystallization with about 1 mL of about 24%) polyethylene glycol buffered to about pH 6.5 with either about 0.1M sodium citrate or about 0.1M sodium cacodylate until crystallization droplets are formed, usually about 4-5 days.
- the crystal structure was determined by combined anomalous scattering from intrinsic sulfur and fortuitous bromide ion as discussed in detail in the Example ' below. c. Methods of using an IGF-1 crystal and its coordinates
- the crystalline IGF-1 herein can be used for various purposes.
- the crystallization process itself further purifies the IGF-1 to homogeneity.
- one such purpose is to provide a highly purified IGF-1 that can be used as a standard or control in a diagnostic setting, for example, as a molecular weight marker, or as an ELISA, radioassay, or radioreceptor assay control.
- crystalline IGF-1 is stable at room temperature, can be lyophilized readily, and is less apt to degrade than less pure compositions.
- crystals of IGF-1 of a size and quality to allow performance of x-ray diffraction studies enable those of skill in the art to conduct studies relating to the binding properties of IGF-1, as well as the binding properties of IGFBPs, IGF-1 receptors, and ALS that associate with the IGF-1.
- structural information derived from a peptide crystal structure can be used for the identification of chemical entities, for example, small organic and bioorganic molecules such as peptidomimetics and synthetic organic molecules that bind IGF-1 and preferably block or prevent an IGF-1- mediated or -associated process or event, or that act as IGF-1 agonists.
- small organic and bioorganic molecules such as peptidomimetics and synthetic organic molecules that bind IGF-1 and preferably block or prevent an IGF-1- mediated or -associated process or event, or that act as IGF-1 agonists.
- the skilled artisan constructs a model of the IGF-1 such as those depicted in Figures 2 and 5. Since every atom of a peptide or polypeptide can be depicted as a sphere of the appropriate van der Waals radius, a detailed surface map of the folded IGF-1 can be constructed. The surface that results is known as the van der Waals surface.
- the "solvent-accessible surface” is the surface that is accessible to a chemical probe, a water molecule herein, and is constructed by rolling a water molecule of appropriate radius on the outside of the peptide maintaining contact with the van der Waals surface.
- Such chemical entities presenting a solvent-accessible surface that mimics the solvent-accessible surface of the IGF-1 can be constructed by those skilled in the art.
- the skilled artisan can search three-dimensional structural databases of compounds to identify those compounds that position appropriate functional groups in similar 3-dimensional structural arrangement, then build combinatorial chemistry libraries around such chemical entities to identify those with high affinity.
- One approach enabled by this invention is the use of the structural coordinates of IGF-1 to design chemical entities that bind to or associate with IGF-1 and alter the physical properties of the chemical entities in different ways.
- properties such as, for example, solubility, affinity, specificity, potency, on/off rates, or other binding characteristics may all be altered and/or maximized.
- the invention also contemplates computational screening of small-molecule databases or designing of chemical entities that can bind in whole or in part to IGF-1. They may also be used to solve the crystal structure of mutants, co-complexes, or the crystalline form of any other molecule homologous to, or capable of associating with, at least a portion of IGF-1.
- An unknown crystal structure which may be any unknown structure, such as, for example, another crystal form of IGF-1, an IGF-1 mutant or peptide, or a co-complex with IGF-1, or any other unknown crystal of a chemical entity that associates with IGF- 1 that is of interest, may be determined using the structural coordinates as set forth in Appendix 1.
- Co-complexes with IGF-1 may include, but are not limited to, IGF-1 -IGFBP-3, IGF-1- IGFBP-3-ALS, IGF-1 -receptor, IGF-1- ⁇ eptide, or IGF-1-small molecule. This method will provide an accurate structural form for the unknown crystal far more quickly and efficiently than attempting to determine such information without the invention herein. The information obtained can thus be used to obtain maximally effective inhibitors or agonists of
- the design of chemical entities that inhibit or agonize IGF-1 generally involves consideration of at least two factors. First, the chemical entity must be capable of physically or structurally associating with IGF-1. The association may be any physical, structural, or chemical association, such as, for example, covalent or noncovalent bonding, or van der Waals, hydrophobic, or electrostatic interactions. Second, the chemical entity must be able to assume a conformation that allows it to associate with
- IGF-1 insulin growth factor-1. Although not all portions of the chemical entity will necessarily participate in the association with IGF-1, those non-participating portions may still influence the overall conformation of the molecule. This in turn may have a significant impact on the desirability of the chemical entity. Such conformational requirements include the overall three-dimensional structure and orientation of the chemical entity in relation to all or a portion of the binding site.
- the potential inhibitory or binding effect of a chemical entity on IGF-1 may be analyzed prior to its actual synthesis and testing by the use of computer-modeling techniques. If the theoretical structure of the given chemical entity suggests insufficient interaction and association between it and IGF-1, the need for synthesis and testing of the chemical entity is obviated. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to bind to IGF-1. Thus, expensive and time-consuming synthesis of inoperative compounds may be avoided.
- An inhibitory or other binding compound of IGF-1 may be computationally evaluated and designed by means of a series of steps in which chemical entities or fragments are screened and selected for their ability to associate with the individual binding sites of IGF-1.
- chemical entities or fragments are screened and selected for their ability to associate with the individual binding sites of IGF-1.
- one skilled in the art may use one of several methods to screen chemical entities or fragments for their ability to associate with IGF-1. This process may begin by visual inspection of, for example, the binding site on a computer screen based on the IGF-1 coordinates in Appendix 1. Selected fragments or chemical entities may then be positioned in a variety of orientations, or "docked," within an individual binding pocket of IGF-1. Docking may be accomplished using software such as Quanta and Sybyl, followed by energy minimization and molecular dynamics with standard molecular mechanics force fields, such as CHAR M and AMBER.
- Specialized computer programs may be of use for selecting interesting fragments or chemical entities. These programs include, for example, GRID, available from Oxford University, Oxford, UK; MCSS or CATALYST, available from Molecular Simulations, Burlington, MA; AUTODOCK, available from Scripps Research Institute, La Jolla, CA; DOCK, available from University of California, San Francisco, CA, and XSITE, available from University College of London, UK.
- GRID available from Oxford University, Oxford, UK
- MCSS or CATALYST available from Molecular Simulations, Burlington, MA
- AUTODOCK available from Scripps Research Institute, La Jolla, CA
- DOCK available from University of California, San Francisco, CA
- XSITE available from University College of London, UK.
- Assembly may be by visual inspection of the relationship of the fragments to each other on the three-dimensional image displayed on a computer screen, in relation to the structural coordinates disclosed herein.
- any molecular modeling techniques may be employed in accordance with the invention; these techniques are known, or readily available to those skilled in the art. It will be understood that the methods and compositions disclosed herein can be used to identify, design, or characterize not only entities that will associate or bind to IGF-1, but alternatively to identify, design, or characterize entities that, like
- IGF-1 will bind to the receptor, thereby disrupting the IGF-1 -receptor interaction.
- the claimed invention is intended to encompass these methods and compositions broadly.
- the efficiency with which that compound may bind to IGF-1 may be tested and modified for the maximum desired characteristic(s) using computational or experimental evaluation.
- Various parameters can be maximized depending on the desired result. These include, but are not limited to, specificity, affinity, on/off rates, hydrophobicity, solubility, and other characteristics readily identifiable by the skilled artisan.
- the invention is useful for the production of small-molecule drug candidates.
- the claimed crystal structures may be also used to obtain information about the crystal structures of complexes of the IGF-1 and small-molecule inhibitors. For example, if the small-molecule inhibitor is co- crystallized with IGF-1, then the crystal structure of the complex can be solved by molecular replacement using the known coordinates of IGF-1- for the calculation of phases. Such information is useful, for example, for determining the nature of the interaction between the IGF-1 and the small-molecule inhibitor, and thus may suggest modifications that would improve binding characteristics such as affinity, specificity, and kinetics. d. Other methods
- the invention herein is also useful in providing a method of identifying indirect agonists of IGF-1 based on the inhibitory properties of N, N-bis(3-D-gluconamido ⁇ ropyl)-deoxycholamine with respect to IGFBPs.
- This method comprises the steps of: comparing the ability of N, N-bis(3-D-gluconamidopro ⁇ yl)- deoxycholamine to inhibit binding of IGFBP-1 or -3 to IGF-1 with the ability of a candidate IGF-1 indirect agonist to inhibit such binding; and determining whether the candidate IGF-1 indirect agonist can inhibit such binding at least as well as N, N-bis(3-D-gluconamidopropyl)-deoxycholamine can so inhibit the binding.
- the comparison is accomplished by competition assay between N, N-bis(3-D- gluconamidopropyl)-deoxycholamine and the candidate IGF-1 indirect agonist, using IC J0 to measure ability to inhibit IGFBP binding.
- inhibition of binding is measured by pre-incubating N, N-bis(3-D-gluconamidopropyl)-deoxycholamine or the candidate agonist molecule with IGF-1 expressed on bacteriophage particles and measuring residual binding of IGF-1 to IGFBP-1 or IGFBP- 3 in a plate-based assay, such as an ELISA.
- the invention further provides a method of identifying indirect agonists of IGF-1 comprising co- crystallizing the candidate agonist with IGF-1 to form a co-crystalline structure and determining if the candidate agonist molecule binds to one or both of two patches on IGF-1.
- the first patch contains the amino acid residues Glu 3, Thr 4, Leu 5, Asp 12, Ala 13, Phe 16, Val 17, Cys 47, Ser 51, Cys 52, Asp 53, Leu 54, and Leu 57
- the second patch contains the amino acid residues Val 11, Ghi 15, Phe 23, Phe 25, Asn 26, Val 44, Phe 49, and Arg 55.
- bmding means that there is at least one contact between each listed amino acid residue of a given patch and the candidate agonist molecule that is less than or equal to 6 angstroms in the co-crystalline structure.
- a candidate agonist molecule will have the property of inhibiting binding of IGFBP-1 or IGFBP-3 to IGF-1.
- the preferred such candidate agonist molecule will inhibit binding of IGFBP-1 or -3 to IGF-1 at least as well as N, N-bis(3-D- gluconamidopropyl)-deoxycholamine. More preferred is the method wherein inhibition of binding is measured using a competition assay between N, N-bis(3-D-gluconamidopro ⁇ yl)-deoxycholamine and the candidate agonist molecule.
- N, N-bis(3-D-gluconamidopropyl)-deoxycholamine detergent herein can be used as a template to perform design of small-molecule drugs that elicit the same effect as the detergent (compete with IGF-1 for IGFBP binding and subsequent disruption of the interaction of IGFBP with IGF-1 to free IGF-1 in situ so that it is active and will interact with the receptor.
- N, N-bis(3-D-gluconamidopropyl)-deoxycholamine lacks an oxygen atom at position CIO. This region of the detergent is in close contact with the side-chain atoms of residues Leu 5, Leu 54, and Leu 57 of IGF-1. Molecules with this same type of conformation would work as indirect IGF-1 agonists.
- the indirect agonist so identified can be used in a method for treating an agonist disorder wherein an effective amount of the indirect agonist of IGF-1 is administered to a mammal with such a disorder.
- the formulation of the indirect agonist herein can be used to treat any condition that would benefit from treatment with IGF-1, including, for example, diabetes, chronic and acute renal disorders, such as chronic renal insufficiency, necrosis, etc., obesity, hyperinsulinemia, GH-insufficiency, Turner's syndrome, short stature, undesirable symptoms associated with aging such as increasing lean-mass-to-fat ratios, immuno-deficiencies including increasing CD4 counts and increasing immune tolerance, catabolic states associated with wasting, etc., Laron dwarfism, insulin resistance, and so forth.
- the indirect agonist composition herein may be directly administered to the mammal by any suitable technique, including orally, parenterally, intranasally, or intrapulmonarily, and can be administered locally or systemically.
- suitable technique including orally, parenterally, intranasally, or intrapulmonarily, and can be administered locally or systemically.
- the specific route of administration will depend, e.g., on the medical history of the patient, including any perceived or anticipated side or reduced effects using IGF-1, and the disorder to be treated.
- parenteral administration include subcutaneous, intramuscular, intravenous, intraarterial, and intraperitoneal administration. Most preferably, the administration is by continuous infusion (using, e.g., minipumps such as osmotic pumps), or by injection (using, e.g., intravenous or subcutaneous means).
- the administration may also be as a single bolus or by slow-release depot formulation.
- the direct agonist is administered orally or by infusion or injection, at a frequency of, preferably, one-half, once, twice, or three times daily, most preferably daily.
- the agonist composition to be used in the therapy will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient
- the site of delivery of the agonist composition is thus determined by such considerations and must be an amount that treats the disorder in question.
- the total pharmaceutically effective amount of agonist administered parenterally per dose will be in the range of about 1 ⁇ g/kg/day up to about 100 mg/kg/day, preferably 10 ⁇ g/kg/day up to about 10 mg/kg/day.
- the agonist is generally administered in doses of about 1 ⁇ g/kg/hour up to about 100 ⁇ g/kg/hour, either by about 1-4 injections per day or by continuous subcutaneous infusions, for example, using a minipump or a portable infusion pump. An intravenous bag solution may also be employed.
- the key factor in selecting an appropriate dose is the result obtained as measured by criteria as are deemed appropriate by the practitioner. If the agonist is administered together with insulin, the latter is used in lower amounts than if used alone, down to amounts which by themselves have little effect on blood glucose, i.e., in amounts of between about 0.1 IU/kg/24 hour to about 0.5 IU/kg/24 hour.
- the agonist is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- a pharmaceutically acceptable carrier i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.
- the formulation is prepared by contacting the agonist uniformly and intimately with a liquid carrier or a finely divided solid carrier or both.
- the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient.
- carrier vehicles include water, saline, Ringer's solution, and dextrose solution.
- Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.
- the carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability.
- Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low-molecular-weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; glycine; amino acids such as glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; nonionic surfactants such as polysorbates, poloxamers, or PEG; and/or neutral salts, e.g.,
- the agonist is typically formulated individually in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at apH of about 4.5 to 8.
- the final formulation if a liquid, is preferably stored at a temperature of about 2-8 °C for up to about four weeks.
- the formulation can be lyophilized and provided as a powder for reconstitution with water for injection that is stored as described for the liquid formulation.
- the agonist to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes).
- Therapeutic agonist compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
- the agonist ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution.
- Recombinant human IGF-1 (rhIGF-1) was obtained as described in the Examples of U.S. Pat. No. 5,723,310 using a polymer/salt combination for phase-forming species and formulated as described in the Examples of U.S. Pat. No. 5,681,814 (acetate, NaCl, polysorbate 20, and benzyl alcohol), and placed in a vial containing 7 ml of 10 mg/ml rhIGF-1. It was desalted into 0.15 M NaCl, 20 mM NaOAc, pH 4.5, and diluted to a final concentration of 10 mg/ml.
- a 4- ⁇ l droplet of the IGF-1 solution was mixed with 5 ⁇ l of reservoir solution (24% polyethylene glycol 3350 buffered to pH 6.5 with 0.1M sodium cacodylate) and 1 ⁇ l of 14 mM of N, N-bis(3-D-gluconamidopropyl)-deoxycholamine, which is obtained in a CRYSTAL
- SCREENTM reagent kit used for crystallization condition screenings and available from Hampton Research, Madison Nigel, CA. This solution was allowed to equilibrate via vapor diffusion (Jancarik et al, supra) with 1 mL of reservoir solution. Thus, a drop of the mixture was suspended under a plastic cover slip over the reservoir solution. Small crystals with a thin, plate-like morphology appeared within 4-5 days. At this point, 2 ⁇ l of 100% methyl pentanediol (MPD) (to a final concentration of 20%) was added to the crystallization droplet, and the crystals dissolved overnight. Within 1 week, crystals reappeared and grew to final dimensions of 0.2 mm X 0.1mm X 0.05 mm with noticeably sharper edges. These crystals were used for all subsequent analysis.
- MPD methyl pentanediol
- crystallization conditions can be varied. By varying the crystallization conditions, other crystal forms of IGF-1 may be obtained. Such variations may be used alone or in combination, and include, for example, varying final protein concentrations between about 5 and 35 mg/ml; varying the IGF-1 -to-precipitant ratio, varying precipitant concentrations between about 20 and 30% for polyethylene glycol, varying pH ranges between about 5.5 and 7.5, varying the concentration or type of detergent, varying the temperature between about -5 and 30°c, and crystallizing IGF-1 by batch, liquid bridge, or dialysis methods using the above conditions or variations thereof. See McPherson et al. (1982), supra. Characterization of IGF-1 crystals
- a single crystal was transferred from the mother liquor to a cryo-protectant solution consisting of 25% (w/v) polyethylene glycol 3350, 30% MPD, 0.2 M sodium cacodylate pH 6.5, 2.8 mM of N, N-bis(3- D-gluconamido ⁇ ropyl)-deoxycholamine, and 1 M NaBr.
- the diffraction was to 1.8 A.
- the crystals were flash-cooled by plunging the solution into liquid nitrogen. The technique of freezing the crystals essentially immortalizes them and produces a much higher quality data set. All subsequent manipulations and x-ray data collection were performed at 100° Kelvin.
- a 4-wavelength MAD data set was collected at beamline 9-2 at the Stanford Synchrotron Radiation Laboratory, with the order of the data sets as follows: Br peak ( ⁇ l), low-energy remote ( ⁇ 2), Br inflection ( ⁇ 3), and high-energy remote ( ⁇ 4).
- the Br peak and inflection points were estimated from fluorescence scans of the crystal, and the low-energy remote was chosen to be 1.54 angstroms, to maximize the small sulfur anomalous signal at this wavelength while minimizing absorption effects. No inverse beam geometry was used.
- Data reduction was performed using Denzo and Scalepack (Otwinowski and Minor, Methods in Enzymology, 276: 307-326 (1997)). To determine the most accurate scale and 5-factors possible, data for all four wavelengths were initially scaled together, assuming no anomalous signal. The scale and -3-factors determined from this scaling run were then applied to each of the four data sets.
- the asymmetric unit of the crystals contained a monomer of IGF-1 bound to a single detergent molecule, yielding a Matthew's coefficient of 2.4 A 3 /Da, or 48.1% solvent.
- the solvent content of the crystals was about 55%.
- the coordinates of the single-bound bromide were determined by manual inspection of the anomalous and dispersive difference Patterson maps.
- the hand ambiguity was resolved by phase refinement using the program SHARP (De La Fortelle and Bricogne, Methods in Enzymology, 276: 472- 494 (1997)) from Global Phasing Limited, 43 Newton Road, Cambridge CB2 2AL, ENGLAND, followed by examination of anomalous-difference Fourier maps calculated using the ⁇ 2 Bijvoet differences.
- SHARP De La Fortelle and Bricogne, Methods in Enzymology, 276: 472- 494 (1997)
- Density modification (solvent flattening and histogram mapping) was performed using DM (Collaborative Computational Project Number 4, Acta Crystallogr., D50: 760-763 (1994); Cowtan, Joint CCP4 and ESF-EACBM Newsletter on Protein Crystallography, 31: 34-38 (1994)), and the resulting electron-density maps were of high quality. Approximately 50% of the structure, corresponding to the three helical regions of IGF-1, was built directly into the experimental electron-density maps using the programs O (Jones et al, Acta Crystallogr., A47: 110-119 (1991)) and QUANTA (version 97.0, MSI, San Diego, CA).
- the final model contains residues 3-34 and 41-64 of IGF-1, one N, N-bis(3-D- gluconamidopro ⁇ yl)-deoxycholamine molecule, one Br, and 50 water molecules.
- the model was refined against the ⁇ 3 data set, since the data statistics demonstrated this data set to be of higher quality than the others. All data from 20- to 1.8-angstrom resolution were included in the refinement, with no application of a sigma cutoff. Secondary structure assignments were made with the program PROMOTIF (Hutchinson and Thornton, Protein Science, 5: 212-220 (1996)).
- the R factor to 1.8 A is 23.7%, and the free R factor is 26.9%, with good stereochemistry.
- the N-terminal B-region corresponds to residues 3-28, the C-region from 29-34, a stretch of poorly ordered residues from 35-40, and the A-region from 42-62.
- the D-region (63-70) is essentially disordered.
- the structure of IGF-1 is similar to insulin (see Figure 3), with a Root-Mean-Squared-Deviation (RMSD) of 3A over backbone atoms that are conserved between the two molecules. Most of these deviations occur in the flexible regions, and when only the helical regions are considered, the RMSD between alpha-carbon atoms is about 0.47A.
- the major difference is the extension of the C-region, for which there is no counterpart in mature insulin, away from the body of the molecule. This loop contains many of the residues that are known to be important for receptor binding. ,
- the detergent molecule binds into a small hydrophobic cleft at the base of the B-helix.
- the preliminary results suggest, without being limited to any one theory, that the detergent does not inhibit binding of these proteins to IGF-1.
- the opposite face of the detergent is making a symmetry contact to the opposite face of IGF-1.
- IGF-1 molecules which results in a symmetric homodimer.
- the buried surface area is 1378 A 2 , which is in the range of physiologically relevant protein-protein interfaces.
- Figure 6 shows that the residues known to be important for receptor binding cluster at this dimer interface. Shown are Tyr24, Thr29, Tyr31, and Tyr60. Mutation of these residues results in anywhere from 6-20X loss in affinity for receptor for individual mutations, or 240->1200X loss in affinity for double mutations. Also shown are Phe23 and Phe25, which are interchangeable with Phe24 and Tyr26 of insulin, with no loss of affinity.
- IGF-1 is composed primarily of three helical segments corresponding to the B-helix (IGF-1 residues 7-18) and two A-helices (IGF-1 residues 43-47 and 54-58) of insulin.
- the hydrophobic core is essentially identical to that described for the NMR structures of IGF-1, including the three disulfide linkages between Cys 6 and Cys 48, Cys 18 and Cys 61, and Cys 47 and Cys 52, as noted in the references above.
- Residues 3 through 6 do not form any regular secondary structure and hence the structure described herein can be classified as being most similar to the T-form of insulin (Derewenda et al, Nature, 338: 594-596 (1989)); indeed, when IGF-1 and the T-form of insulin are superimposed on the C ⁇ positions of their respective helical segments (IGF-1 residues 8-19, 42-49, and 54-61; insulin residues B9-B20, A1-A8, and A13-A20) the RMSD is only 0.93 angstroms. As in insulin, residues 18-21 at the end of the B-helix form a type IF ⁇ -turn, which redirects the backbone from the B-helix into an extended region.
- Residues 24-27 form a type VIII ⁇ -turn in to accommodate the C-region, which extends away from the core of IGF-1, and interacts with a symmetry-related molecule.
- Residues 30-33 form a well-defined type II beta-turn, prominently displaying Tyr 31 at the i+1 position.
- Residues 35-40 have not been modeled, as the electron density in this region is weak and disconnected. Only the first two residues of the D-region (residues 63 and 64) are ordered in the structure.
- the C-region of IGF-1 mediates a two-fold symmetric crystal-packing interaction across the ⁇ -axis of the unit cell.
- This interaction buries 689 A 2 of solvent-accessible surface area from each molecule of IGF-1, or 1378 A 2 total, and is the largest interface in the crystal.
- a total of 28 intermolecular contacts of distance 3.6 A or less are formed via this interface, with the next most extensive crystal packing interaction forming only nine contacts.
- the core of the interface is dominated by Tyr24 and Pro28 from each monomer, which bury 39 A 2 and 57 A 2 of solvent-accessible surface area, respectively.
- Tyr 31 which lies at the tip of the loop at the furthest point from the core of IGF-1, packs against the phenolic rings of Phe 23 and Phe 25 of the symmetry-related molecule.
- two main-chain hydrogen bonds (Tyr 31 N-Phe 23 O; Ser 34 N-Asp 20 O) are present in the dimer interface.
- Residues from the D-region (62-64) are also partially sequestered by dimer formation. Because of these interactions, most of the C-region in the crystal is well-ordered, providing the first high- resolution view of the conformation of this biologically important loop.
- N, N-bis(3-D- gluconamido ⁇ ropyl)-deoxycholamine interacts with residues, forming a small hydrophobic cleft on one surface of IGF-1 (Leu 5, Phe 16, Val 17, Leu 54, and Leu 57) (Fig. 7A).
- the preference for N, N-bis(3-D- gluconamidopropyl)-deoxycholamine is explained, without being limited to any one theory, by the absence of an oxygen atom at position CIO in the detergent molecule. This region of the detergent is in close contact with the side chain atoms of residues Leu 5, Leu 54, and Leu 57 in IGF-1.
- the opposite face of the detergent mediates a symmetry contact with residues Val 11 , Leu 14, and Gin 15 of a symmetry-related
- One patch has the amino acid residues Glu 3, Tlir 4, Leu 5, Asp 12, Ala 13, Phe 16, Val 17, Cys 47, Ser 51, Cys 52, Asp 53, Leu 54, and Leu 57, and the second patch has the amino acid residues Val 11, Gin 15, Phe 23, Phe 25, Asn 26, Val 44, Phe 49, and Arg 55. Binding is defined by having at least one contact between each listed amino acid residue and the candidate agonist molecule that is less than or equal to 6 angstroms.
- the C-region in the IGF-1 crystal structure extends out from the core of the molecule, with residues 30-33 forming a canonical type II beta-turn, and the remainder of the C-region forming a crystallographic dimer with a symmetry-related molecule.
- Tyr 31 has been implicated as being a critical determinant for IGF-IR binding, and its location at the tip of this extension places it in an ideal location to interact with a receptor molecule.
- this region of IGF-1 is not well-defined by NMR data, the conformation of the C-region in the crystal is likely to reflect the solution conformation. There is evidence of a reverse turn at the tip of the loop and a hinge bending at the loop termini of IGF-2 (Torres et al, supra).
- crystal packing forces undoubtedly help stabilize the orientation of this loop, its conformation is consistent with the solution structure of the closely related IGF-2.
- the size of the interface formed by the crystallographic dimer is well within the range of buried surface area in known biological complexes (Janin and Chothia, J. Biol Chem., 264: 16027-16030 (1990)). In addition, this interaction partially excludes from solvent several of the residues known to be important for binding to the IGF-IR, including Phe 23 (69% buried), Tyr 24 (64%), Phe 25 (29%), and Tyr 31 (38%). Other groups have also reported homodimeric interactions of IGF-1 and IGF-2.
- the known binding stoichiometry of one IGF-1 molecule per receptor dimer makes it difficult to rationalize the biological significance of IGF-1 dimerization.
- the IGF-1 dimer in this crystal form results from the high concentration of IGF-1 in the crystallization experiment, and does not represent a physiologically relevant form of the molecule.
- the crystal structure of IGF-1 has been determined using anomalous scattering from the intrinsic sulfur atoms and a Br- ion bound at a fortuitous halide-binding site.
- the structure is very similar to insulin, with the only major difference being the C-region, which protrudes from the body of the protein and mediates a homodimeric interaction.
- the amount of buried surface area is consistent with the feet that at neutral pH, IGF-1 undergoes self-association in a concentration-dependent manner.
- several residues that are important for receptor binding are found at this dimer interface, suggesting, without being limited to any one theory, that effects on receptor binding by mutation of these residues may be a result of disruption of the dimer, rather than direct contact with the receptor surface.
- NMR-derived diffusion measurements were used to estimate the K . for the interaction between IGF-1 and N, N-bis(3-D-gluconamidopropyl)-deoxycholamine.
- Samples were prepared in 50 mM phosphate buffer in D 2 0, pH 6.5 (uncorrected meter reading), and contained: 1.0 mM N, N-bis(3-D- gluconamidopropyl)-deoxycholamine + 0.5 mM IGF-1; 0.5 mM N, N-bis(3-D-gluconamidopropyl)- deoxycholamine + 0.25 mM IGF-1; 0.25 mM N, N-bis(3-D-gluconamido ⁇ ropyl)-deoxycholamine + 0.125 mM IGF-1; or N, N-bis(3-D-gluconamidopro ⁇ yl)-deoxycholamine only (1.0, 0.5, or 0.25 mM).
- Spectra were collected with 128 to 1024 transients as the z-gradient strength was increased from 0.009 to 0.45 T» ⁇ n l in 18 equal increments; measurements were made at least twice on each sample. Spectra were processed and peak heights extracted with the program FELLX (v98.0, MSI, San Diego). Diffusion constants, proportion of bound detergent, and resulting K. were extracted as described by Fejzo et al, Chemistry & Biology, 6: 755-769 (1999).
- E. coli cells (XLl-Blue, Stratagene) freshly transformed with the phage vector pIGF-g3 displaying human IGF-1 as described in Dubaquie and Lowman, supra, were grown overnight in 5 ml of 2YT medium (Sambrook et al, Molecular Cloning: A Laboratory Handbook (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989)).
- the phage particles displaying IGF-1 were titered against IGFBP-1 and
- IGFBP-3 to obtain a 500- 1000-fold dilution for preincubation with serial dilutions of the detergents and binding protein standards for 35 minutes.
- Microwell clear polystyrene immunoplates with a MAXISORPTM surface (Nunc, Denmark) were coated with IGFBP-1 or IGFBP-3 protein overnight at 4°C (50 ⁇ l at 3 ⁇ g/mL in 50 mM carbonate buffer, pH 9.6), blocked with 0.5% TWEEN® 20 polyoxyethylene sorbitan monolaurate (Atlas Chemical Co.), and PBS and washed eight times with PBS, 0.05% TWEEN® 20 polyoxyethylene sorbitan monolaurate. The samples were added to the plates for 30 minutes. Plates were washed eight times with PBS, 0.05% TWEEN® 20 polyoxyethylene sorbitan monolaurate, incubated with
- the self-association of IGF-1 was determined by sedimentation equilibrium analysis.
- the experiments were conducted at 20°C in an OPTIMATM XL-A XL-I analytical ultracentrifuge (Beckman Coulter, Inc.).
- the samples were prepared in 0.1 M citrate buffer, pH 6.5, 75 mM NaCl with a loading concentration from 1 mM to 0.01 mM.
- the concentration gradients were measured at rotor speeds of 25000 and 30000 rpm at 280 nm or 285 nm using a scanning absorption optical system.
- the attainment of an equilibrium state was verified by comparing successive scans after approximately 16 hours.
- the partial specific volume of IGF-1 was calculated from its amino acid composition.
- K. values of 220, 440, and 430 ⁇ M were obtained, respectively.
- This technique has routinely been applied to small molecules (several hundred Daltons molecular weight or less) binding to large proteins.
- the ligand is relatively large (862 Da) and the protein is relatively small (7648 Da); hence, the differential decrease in diffusion constant on binding is small This increases the uncertainty with which the dissociation constant can be measured.
- the data described above suggest that the K. for the interaction between N, N- bis(3-D-gluconamidopro ⁇ yl)-deoxycholamine and IGF-1 is 300+150 ⁇ M.
- a similar analysis of the (3-(3- cholamidopropyl) dimethylammonio)-l -propane sulphonate diffusion data suggests that that K. in this case is greater than 3 mM.
- N, N-bis(3-D-gluconamidopropyl)-deoxycholamine blocks IGFBP-1 and IGFBP-3 binding.
- the detergent was preincubated with IGF-1 expressed on bacteriophage particles, and the level of residual binding to IGFBP-1 and IGFBP-3 was measured in a plate-based assay (ELISA).
- ELISA plate-based assay
- N N-bis(3-D-gluconamidopropyl)-deoxycholamine completely inhibited IGF-1 on phage from binding to IGFBP-1 and IGFBP-3 with IC 50 values of 740+260 ⁇ M and 231+29 ⁇ M, respectively. These numbers must be interpreted conservatively, however, since the critical micelle concentration of N, N-bis(3-D- gluconamidopropyl)-deoxycholamine (1.4 mM) presents an upper limit on the curve in Figure 8.
- the sedimentation equilibrium data show that IGF-1 undergoes self-association in solution.
- the average molecular weight increased with increasing protein concentration from 0.01 mM to 1 mM.
- the average molecular weight at the highest concentration studied (1 mM) is about 37% higher than the monomer molecular weight (10.4 KDa at 1 mM versus 7.6 KDa monomer molecular weight).
- concentrations below 0.05 mM no self-association was observed, and IGF-1 exists only as a monomer in solution at neutral pH. If it is assumed that the higher-molecular-weight species are IGF-1 dimers, the sedimentation data can be fit as a monomer-dimer model with a K d of 3.6+ 1.0 mM ( Figure 9) .
- Patch I consists of Glu 7, Leu 10, Val 11, Leu 14, Phe 25, lie 43, and Val 44, while patch 2 consists of Glu 3, Thr 4, Leu 5, Phe 16, Val 17, and Leu 54. In the crystal structure of IGF-1, these two patches are involved in detergent-mediated crystal packing contacts.
- Patch 1 of the crystal structure of IGF-1 consists of amino acid residues Glu 3, Thr 4, Leu 5, Asp 12, Ala 13, Phe 16, Val 17, Cys 47, Ser 51, Cys 52, Asp 53, Leu 54, and Leu 57
- Patch 2 of the crystal structure of IGF-1 consists of amino acid residues Val 11, Gin 15, Phe 23, Phe 25, Asn 26, Val 44, Phe 49, and Arg 55, wherein binding occurs if there is at least one contact between each listed amino acid residue and the candidate agonist molecule that is less than or equal to 6 angstroms.
- N, N-bis(3-D-gluconamidopro ⁇ yl)-deoxycholamine does not inhibit IGF-1R- mediated signaling in a cell-based receptor activation assay.
- N, N-bis(3- D-gluconamidopropyl)-deoxycholamine as an inhibitor of IGFBP interactions allows the ability to develop small-molecule drugs or peptidomimetics that disrupt the IGF-1/IGFBP complex in vivo, thereby releasing receptor-active IGF-1 from the systemic, inactive pool.
- drugs include orally bioavailable therapy for metabolic disease such as diabetes.
- Zeslawski et al. EMBO J., 20: 3638-3644 (2001) published the crystal structure of IGF- 1 in complex with the N-terminal domain of IGFBP-5.
- IGF-F 1-1 The complex between peptide IGF-F 1-1 and IGF- 1 was determined from NMR spectroscopy data collected at 600 and 800 MHz.
- IGF-1 uniformly labeled with 13 C and I5 N was prepared using the scheme outlined by Reilly and Fairbrother, J. Biomol NMR, 4: 459-462 (1994) and purified according to the protocol in Vajdos et al, supra.
- a slight molar excess of unlabeled IGF-Fl-1 was mixed with a 1.5 mM solution of 13 C/ 15 N IGF-1 and 'H, 13 C, and 15 N N NMR resonances assigned from double- and triple-resonance NMR experiments as described by Cavanagh et al.
- Intermolecular restraints between IGF-1 and the peptide were obtained from an ⁇ l -filtered, ⁇ 2- edited 13 C HSQC-NOESY spectrum (Lee et al, FEBS Lett., 350: 87-90 (1994)).
- Intrapeptide distance restraints were obtained from a 2-D 13 C-filtered NOESY spectrum.
- ⁇ dihedral angle restraints were obtained from an HNHA spectrum (Cavanagh et al, supra), and ⁇ l restraints were derived from HNHB and short-mixing-time TOCSY spectra (Clore et al, J. Biomolec. NMR, 1: 13-22 (1991)).
- IGF-Fl-1 adopts a conformation very similar to that determined for the peptide by itself in solution.
- the conformation of IGF- 1 contains three helices (residues 7-18, 43-49, and 54-60) and is similar to that seen at lower resolution in previous NMR studies of uncomplexed IGF-1 (see e.g. Cooke et al, supra; Sato et al, supra; and Laajoki et al, supra).
- Fig. 10 shows the comparison for the detergent and phage peptide complexes.
- Fig. 10A shows a ribbon diagram of a complex of IGF-1 and N, N-bis(3-D-gluconamidopropyl)- deoxycholamine), and
- Fig. 10B shows a complex of IGF-1 bound to the phage-derived peptide IGF-Fl-1.
- the B-region (helix I) adopts a very similar conformation in both complexes.
- the C-loop is only partially ordered in the detergent complex, and ill defined in the peptide complex.
- AATTOOMM 8800 CCGG LLEEUU AA 1144 26.457 13.638 31.695 1.00 15.59
- ATOM 214 N TYR A 31 32.265 -8.32529.275 1.0023.05
- ATOM 215 CA TYR A 31 32.723 -9.57628.690 1.0025.72
- ATOM 309 CA ARG A 50 25.381 16.219 17.640 1.00 26.05
- ATOM 310 CB ARG A 50 25.106 14.832 17.157 1.0023.82
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06026833A EP1801120A1 (en) | 2001-02-09 | 2002-02-01 | Co-crystalline complex of IGF-1 and methods of identifying indirect agonists of IGF-1 using the same |
EP06026832A EP1772464B1 (en) | 2001-02-09 | 2002-02-01 | Methods of identifying indirect agonists of IGF-1 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26797701P | 2001-02-09 | 2001-02-09 | |
US267977P | 2001-02-09 | ||
US28707201P | 2001-04-27 | 2001-04-27 | |
US287072P | 2001-04-27 | ||
PCT/US2002/003156 WO2002064627A2 (en) | 2001-02-09 | 2002-02-01 | Crystallization of igf-1 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06026832A Division EP1772464B1 (en) | 2001-02-09 | 2002-02-01 | Methods of identifying indirect agonists of IGF-1 |
EP06026833A Division EP1801120A1 (en) | 2001-02-09 | 2002-02-01 | Co-crystalline complex of IGF-1 and methods of identifying indirect agonists of IGF-1 using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1358209A2 true EP1358209A2 (en) | 2003-11-05 |
EP1358209B1 EP1358209B1 (en) | 2006-12-27 |
Family
ID=26952796
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06026833A Withdrawn EP1801120A1 (en) | 2001-02-09 | 2002-02-01 | Co-crystalline complex of IGF-1 and methods of identifying indirect agonists of IGF-1 using the same |
EP06026832A Expired - Lifetime EP1772464B1 (en) | 2001-02-09 | 2002-02-01 | Methods of identifying indirect agonists of IGF-1 |
EP02724908A Expired - Lifetime EP1358209B1 (en) | 2001-02-09 | 2002-02-01 | Crystallization of igf-1 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06026833A Withdrawn EP1801120A1 (en) | 2001-02-09 | 2002-02-01 | Co-crystalline complex of IGF-1 and methods of identifying indirect agonists of IGF-1 using the same |
EP06026832A Expired - Lifetime EP1772464B1 (en) | 2001-02-09 | 2002-02-01 | Methods of identifying indirect agonists of IGF-1 |
Country Status (20)
Country | Link |
---|---|
US (8) | US7084240B2 (en) |
EP (3) | EP1801120A1 (en) |
JP (2) | JP4489352B2 (en) |
KR (1) | KR100872613B1 (en) |
CN (1) | CN100439397C (en) |
AT (2) | ATE439378T1 (en) |
AU (1) | AU2002255508B2 (en) |
BR (1) | BR0207422A (en) |
CA (1) | CA2431033A1 (en) |
DE (3) | DE60233359D1 (en) |
DK (2) | DK1358209T3 (en) |
ES (2) | ES2278020T3 (en) |
HK (1) | HK1060138A1 (en) |
HU (1) | HUP0500733A3 (en) |
IL (2) | IL156435A0 (en) |
MX (1) | MXPA03007042A (en) |
NZ (3) | NZ526672A (en) |
PL (1) | PL374181A1 (en) |
WO (1) | WO2002064627A2 (en) |
ZA (1) | ZA200304900B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4117731B2 (en) * | 2001-03-14 | 2008-07-16 | ジェネンテック・インコーポレーテッド | IGF antagonist peptide |
US6861406B2 (en) * | 2001-09-18 | 2005-03-01 | Bioexpertise, Llc | IGF-binding protein-derived peptide |
US6914049B2 (en) * | 2001-09-18 | 2005-07-05 | Bioexpertise, Llc | IGF-binding protein-derived peptide or small molecule |
EP1627323A4 (en) * | 2003-05-06 | 2008-04-09 | New Century Pharmaceuticals | Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on therir albumin binding properties |
US20070043509A1 (en) * | 2003-11-03 | 2007-02-22 | Carter Daniel C | Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties |
BRPI0418589A (en) * | 2003-12-08 | 2008-01-29 | Bentley Pharmaceuticals Inc | pharmaceutical compositions and methods for insulin treatment |
WO2006001911A2 (en) * | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor beta chain and methods of use |
WO2005108424A1 (en) * | 2004-05-06 | 2005-11-17 | Genentech, Inc. | Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use |
CA2910494C (en) | 2004-07-19 | 2018-10-23 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
EP1848812A4 (en) * | 2004-10-01 | 2011-11-09 | Life Technologies Corp | Feeding buffers, systems, and methods for in vitro synthesis of biomolecules |
US7556776B2 (en) * | 2005-09-08 | 2009-07-07 | President And Fellows Of Harvard College | Microfluidic manipulation of fluids and reactions |
BRPI0812768A2 (en) * | 2007-06-08 | 2014-12-02 | Massachusetts Inst Technology | IGF FOR TREATMENT OF RETT SYNDROME AND SYNAPTIC DISORDERS. |
US8350007B2 (en) | 2007-08-17 | 2013-01-08 | The Regents Of The University Of California | Crystal structure of human mitoNEET protein |
CN101139391B (en) * | 2007-08-21 | 2012-07-25 | 陈志南 | CD147 extracellular domain crystal structure and use thereof |
US9664619B2 (en) * | 2008-04-28 | 2017-05-30 | President And Fellows Of Harvard College | Microfluidic device for storage and well-defined arrangement of droplets |
WO2011011071A2 (en) * | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
KR101417872B1 (en) * | 2009-07-22 | 2014-07-09 | 입센 파마 에스.에이.에스 | Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59 |
US20120266263A1 (en) * | 2009-10-14 | 2012-10-18 | Mount Sinai School Of Medicine | Method of treating memory disorders and enhancing memory using igf-ii compounds |
EP2830625A1 (en) * | 2012-03-28 | 2015-02-04 | Merck Sharp & Dohme Corporation | Insulin-like growth factor-1 receptor inhibitors |
KR101711584B1 (en) * | 2012-12-18 | 2017-03-02 | 재단법인 의약바이오컨버젼스연구단 | Crystal Structure and Crystallization of modified EPRS protein |
WO2015095650A1 (en) | 2013-12-19 | 2015-06-25 | Puretein Bioscience Llc. | Methods for treating an animal |
US20240050455A1 (en) * | 2020-06-01 | 2024-02-15 | Loma Linda University Health | Methods of treatment of a cytokine storm |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US589867A (en) * | 1897-09-14 | Clothes-line hanger | ||
US577276A (en) * | 1897-02-16 | Quarter-saver iv | ||
US4672108A (en) * | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
DE3327709A1 (en) * | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | INSULIN DERIVATIVE CRYSTAL SUSPENSIONS, METHOD FOR THE PRODUCTION AND USE THEREOF |
AU598205B2 (en) * | 1985-08-22 | 1990-06-21 | Gropep Pty Ltd | Peptide analogues of mammalian insulin-like growth factor-1 |
DE3717370A1 (en) * | 1987-05-22 | 1988-12-01 | Hoechst Ag | MIXED CRYSTALS FROM INSULIN AND INSULINE DERIVATIVES, METHOD FOR THE PRODUCTION OF THESE MIXED CRYSTALS, PHARMACEUTICAL AGENTS CONTAINING THESE MIXED CRYSTALS AND THEIR USE FOR TREATING DIABETES MELLITUS |
US4833233A (en) * | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
SE8703625D0 (en) | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | NEW MEDICAL USE |
US4876242A (en) * | 1987-09-21 | 1989-10-24 | Merck & Co., Inc. | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast |
JP2507106B2 (en) * | 1987-12-24 | 1996-06-12 | グロペップ プロプライエタリー リミテッド | Insulin-like growth factor 1 (IGF-1) or factor 2 (IGF-2) related peptides |
US5470828A (en) * | 1987-12-24 | 1995-11-28 | Gropep Pty. Ltd. | Peptide analogs of insulin-like growth factor II |
US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
DE68905203T2 (en) * | 1988-02-05 | 1993-07-22 | Ciba Geigy Ag | USE OF IGF I FOR PRODUCING A PREPARATION FOR THE TREATMENT OF KIDNEY DISEASES. |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
GB8920381D0 (en) | 1989-09-08 | 1989-10-25 | Greater Glasgow Health Board | Treatment of insulin-resistant diabetes |
US5028224A (en) * | 1990-01-09 | 1991-07-02 | Kimberly-Clark Corporation | Apparatus for intermittently depositing particulate material in a substrate |
US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
US5681814A (en) | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
US5374620A (en) * | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
SE9100099D0 (en) | 1991-01-11 | 1991-01-11 | Kabi Pharmacia Ab | USE OF GROWTH FACTOR |
US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
EP0597033B1 (en) * | 1991-08-01 | 1997-04-09 | Genentech, Inc. | Igf-1 to improve the neural condition |
US5126314A (en) * | 1991-09-06 | 1992-06-30 | Eastman Kodak Company | Mixture of dyes for black dye donor for thermal color proofing |
US6310040B1 (en) | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
JPH07508025A (en) | 1992-05-08 | 1995-09-07 | トーマス・ジェファーソン・ユニバーシティ | Insulin-like growth factor (IGF-1) analogs |
SE9201573D0 (en) | 1992-05-19 | 1992-05-19 | Kabi Pharmacia Ab | USE OF IGF-1 |
WO1993025687A1 (en) | 1992-06-09 | 1993-12-23 | Chiron Corporation | Crystallization of m-csf |
CA2136969C (en) * | 1992-06-12 | 2009-03-24 | Michael E. Lewis | Prevention and treatment of peripheral neuropathy |
GB9217696D0 (en) | 1992-08-20 | 1992-09-30 | Agricultural & Food Res | Use of specific binding molecules |
US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
CA2132871A1 (en) | 1993-01-25 | 1994-08-04 | Alan C. Moses | Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties |
DK72793D0 (en) | 1993-06-21 | 1993-06-21 | Novo Nordisk As | NEW PRODUCT |
US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
US5407810A (en) | 1993-08-20 | 1995-04-18 | Genentech, Inc. | Aqueous multiple-phase isolation of polypeptide |
US5504188A (en) * | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
SE9402370D0 (en) | 1994-07-04 | 1994-07-04 | Pharmacia Ab | Use of IGF-I |
US5597893A (en) * | 1994-10-31 | 1997-01-28 | Eli Lilly And Company | Preparation of stable insulin analog crystals |
AR002976A1 (en) * | 1995-03-31 | 1998-05-27 | Lilly Co Eli | PARENTERAL PHARMACEUTICAL FORMULATIONS OF LONG-TERM EFFECT OF INSULIN; CRYSTALS OF SUCH ANALOGUES APPLICABLE IN SUCH FORMULATIONS AND PROCEDURE OF THE FORMULATIONS MENTIONED |
SE9501472D0 (en) | 1995-04-21 | 1995-04-21 | Pharmacia Ab | Truncated IGF-I |
EP0833847B1 (en) | 1995-06-22 | 2003-09-24 | Biogen, Inc. | Crystals of fragments of cd40 ligand and their use |
US5948751A (en) * | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
JP3417230B2 (en) * | 1996-09-25 | 2003-06-16 | 信越化学工業株式会社 | Photocurable liquid silicone rubber composition for mold making |
US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
US5898028A (en) * | 1997-03-20 | 1999-04-27 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
US6121416A (en) * | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
EP1001991A4 (en) | 1997-07-03 | 2005-01-26 | Smithkline Beecham Corp | CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN |
US5876242A (en) * | 1997-07-21 | 1999-03-02 | Williams; Hugh D. | Remote battery extension apparatus |
EP1057026A4 (en) | 1998-01-21 | 2005-10-05 | Brigham & Womens Hospital | Circulating insulin-like growth factor-i and prostate cancer risk |
AU6515499A (en) | 1998-10-16 | 2000-05-08 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
JP2004512010A (en) | 2000-03-29 | 2004-04-22 | ディージーアイ・バイオテクノロジーズ・エル・エル・シー | Insulin and IGF-1 receptor agonists and antagonists |
EP1399475A2 (en) | 2001-06-07 | 2004-03-24 | F. Hoffmann-La Roche Ag | Mutants of igf binding proteins and methods of production of antagonists thereof |
US20040137518A1 (en) * | 2002-01-31 | 2004-07-15 | Lambert Millard Hurst | CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME |
JP3680801B2 (en) * | 2002-02-27 | 2005-08-10 | 株式会社デンソー | Winding joining method for rotating electrical machines |
-
2002
- 2002-02-01 AU AU2002255508A patent/AU2002255508B2/en not_active Ceased
- 2002-02-01 NZ NZ526672A patent/NZ526672A/en not_active IP Right Cessation
- 2002-02-01 US US10/066,009 patent/US7084240B2/en not_active Expired - Fee Related
- 2002-02-01 JP JP2002564956A patent/JP4489352B2/en not_active Expired - Fee Related
- 2002-02-01 BR BR0207422-2A patent/BR0207422A/en not_active Application Discontinuation
- 2002-02-01 EP EP06026833A patent/EP1801120A1/en not_active Withdrawn
- 2002-02-01 EP EP06026832A patent/EP1772464B1/en not_active Expired - Lifetime
- 2002-02-01 ES ES02724908T patent/ES2278020T3/en not_active Expired - Lifetime
- 2002-02-01 DE DE60233359T patent/DE60233359D1/en not_active Expired - Lifetime
- 2002-02-01 KR KR1020037010465A patent/KR100872613B1/en not_active IP Right Cessation
- 2002-02-01 DK DK02724908T patent/DK1358209T3/en active
- 2002-02-01 IL IL15643502A patent/IL156435A0/en unknown
- 2002-02-01 DE DE60217066T patent/DE60217066T4/en not_active Expired - Lifetime
- 2002-02-01 DE DE60217066A patent/DE60217066D1/en not_active Expired - Lifetime
- 2002-02-01 NZ NZ548358A patent/NZ548358A/en not_active IP Right Cessation
- 2002-02-01 HU HU0500733A patent/HUP0500733A3/en unknown
- 2002-02-01 MX MXPA03007042A patent/MXPA03007042A/en active IP Right Grant
- 2002-02-01 AT AT06026832T patent/ATE439378T1/en active
- 2002-02-01 DK DK06026832T patent/DK1772464T3/en active
- 2002-02-01 NZ NZ548359A patent/NZ548359A/en not_active IP Right Cessation
- 2002-02-01 PL PL02374181A patent/PL374181A1/en not_active Application Discontinuation
- 2002-02-01 CA CA002431033A patent/CA2431033A1/en not_active Abandoned
- 2002-02-01 EP EP02724908A patent/EP1358209B1/en not_active Expired - Lifetime
- 2002-02-01 WO PCT/US2002/003156 patent/WO2002064627A2/en active IP Right Grant
- 2002-02-01 CN CNB028047079A patent/CN100439397C/en not_active Expired - Fee Related
- 2002-02-01 ES ES06026832T patent/ES2331150T3/en not_active Expired - Lifetime
- 2002-02-01 AT AT02724908T patent/ATE349469T1/en active
-
2003
- 2003-06-12 IL IL156435A patent/IL156435A/en not_active IP Right Cessation
- 2003-06-24 ZA ZA2003/04900A patent/ZA200304900B/en unknown
-
2004
- 2004-05-03 HK HK04103092A patent/HK1060138A1/en not_active IP Right Cessation
-
2005
- 2005-04-14 US US11/107,672 patent/US7238658B2/en not_active Expired - Fee Related
-
2006
- 2006-06-20 US US11/471,897 patent/US7433788B2/en not_active Expired - Fee Related
- 2006-06-20 US US11/472,122 patent/US20060270839A1/en not_active Abandoned
- 2006-06-20 US US11/471,895 patent/US20060276397A1/en not_active Abandoned
- 2006-06-20 US US11/471,896 patent/US7596455B2/en not_active Expired - Fee Related
- 2006-06-20 US US11/472,121 patent/US7354769B2/en not_active Expired - Fee Related
- 2006-06-20 US US11/471,912 patent/US7297763B2/en not_active Expired - Fee Related
-
2009
- 2009-04-06 JP JP2009092074A patent/JP2009215299A/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO02064627A2 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7297763B2 (en) | Crystallization of IGF-1 | |
AU2002255508A1 (en) | Crystallization of IGF-1 | |
Vajdos et al. | Crystal structure of human insulin-like growth factor-1: detergent binding inhibits binding protein interactions | |
Keeler et al. | The tertiary structure and backbone dynamics of human prolactin | |
Siwanowicz et al. | Structural basis for the regulation of insulin-like growth factors by IGF binding proteins | |
US20090117662A1 (en) | Mutants of IGF Binding Proteins and Methods of Production of Antagonists Thereof | |
US20150198619A1 (en) | Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain | |
Watson | Insulin analogues for insulin receptor studies and medical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030801 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ULTSCH, MARK Inventor name: SCHAFFER, MICHELLE Inventor name: VAJDOS, FELIX |
|
17Q | First examination report despatched |
Effective date: 20031230 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1060138 Country of ref document: HK |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061227 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60217066 Country of ref document: DE Date of ref document: 20070208 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070228 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: RENTSCH & PARTNER |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20070400888 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070528 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2278020 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1060138 Country of ref document: HK |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20070928 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061227 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070201 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: RENTSCH & PARTNER;FRAUMUENSTERSTRASSE 9, POSTFACH 2441;8022 ZUERICH (CH) |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061227 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: GENENTECH, INC. Free format text: GENENTECH, INC.#1 DNA WAY#SOUTH SAN FRANCISCO, CA 94080-4990 (US) -TRANSFER TO- GENENTECH, INC.#1 DNA WAY#SOUTH SAN FRANCISCO, CA 94080-4990 (US) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20120214 Year of fee payment: 11 Ref country code: FR Payment date: 20120221 Year of fee payment: 11 Ref country code: IE Payment date: 20120210 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20120125 Year of fee payment: 11 Ref country code: TR Payment date: 20120110 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20120201 Year of fee payment: 11 Ref country code: SE Payment date: 20120215 Year of fee payment: 11 Ref country code: IT Payment date: 20120215 Year of fee payment: 11 Ref country code: GR Payment date: 20120113 Year of fee payment: 11 Ref country code: BE Payment date: 20120214 Year of fee payment: 11 Ref country code: DK Payment date: 20120210 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20120217 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20120126 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20120112 Year of fee payment: 11 |
|
BERE | Be: lapsed |
Owner name: GENENTECH, INC. Effective date: 20130228 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20130901 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 349469 Country of ref document: AT Kind code of ref document: T Effective date: 20130228 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20070400888 Country of ref document: GR Effective date: 20130904 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20130201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130202 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130901 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130904 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20131031 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60217066 Country of ref document: DE Effective date: 20130903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130201 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130201 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130903 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130201 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20140509 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130202 |